使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Greetings, and welcome to Align Technology First Quarter 2019 Earnings Conference Call. (Operator Instructions) Please note, this conference is being recorded. I would now like to turn the conference over to Shirley Stacy, Vice President, Corporate and Investor Communications. Thank you. You may begin.
各位好,歡迎參加 Align Technology 2019 年第一季財報電話會議。(接線員指示) 請注意,本次會議將被錄音。現在我想把會議交給企業與投資人溝通副總裁 Shirley Stacy。謝謝。您可以開始了。
Shirley Stacy - VP of Corporate Communications & IR
Shirley Stacy - VP of Corporate Communications & IR
Thank you. Good afternoon, and thank you for joining us. I'm Shirley Stacy, Vice President of Corporate and Investor Communications. Joining me today is Joe Hogan, President and CEO; and John Morici, CFO.
謝謝。各位下午好,感謝各位加入我們。我是 Shirley Stacy,企業與投資人溝通副總裁。今天與我一同出席的有總裁暨執行長 Joe Hogan,以及財務長 John Morici。
We issued first quarter 2019 financial results today via GlobeNewswire, which is available on our website at investor.aligntech.com. Today's conference call is being audio webcast and will be archived on our website for approximately 12 months. A telephone replay will be available today by approximately 5:30 p.m. Eastern time through 5:30 p.m. Eastern time, May 8.
我們今天透過 GlobeNewswire 發布了 2019 年第一季財務結果,可於我們的網站 investor.aligntech.com 取得。今天的電話會議將以音訊方式網路直播,並將在我們的網站上存檔約 12 個月。電話重播預計將於今天約下午 5:30(美東時間)提供,並持續至 5 月 8 日下午 5:30(美東時間)。
To access the telephone replay, domestic callers should dial (877) 660-6853 with conference number 13689188, followed by #. International callers should dial (201) 612-7415 with the same conference number.
如欲收聽電話重播,美國境內來電者請撥 (877) 660-6853,會議號碼 13689188,然後按 #。國際來電者請撥 (201) 612-7415,會議號碼相同。
As a reminder, the information that the presenters discuss today will include forward-looking statements, including statements about Align's future events, product outlook and the expected financial results for the second quarter of 2019. These forward-looking statements are only predictions and involve risks and uncertainties that are set forth in more detail in our most recent periodic reports filed with the Securities and Exchange Commission. Actual results may vary significantly, and Align expressly assumes no obligation to update any forward-looking statements. We've posted historical financial statements, including the corresponding reconciliations and our first quarter 2019 conference call slides on our webcast under Quarterly Results. Please refer to these files for more detailed information. With that, I'll turn the call over to Align Technology's President and CEO, Joe Hogan. Joe?
提醒各位,今天簡報者所討論的資訊將包含前瞻性陳述,包括關於 Align 未來事件、產品展望,以及 2019 年第二季預期財務結果的陳述。這些前瞻性陳述僅為預測,並涉及風險與不確定性;相關內容已在我們最近向美國證券交易委員會提交的定期報告中更詳細說明。實際結果可能有重大差異,Align 明確表示不承擔更新任何前瞻性陳述之義務。我們已在網路直播的「季度結果」項下張貼歷史財務報表(含相應調節表)以及 2019 年第一季電話會議投影片。如需更詳細資訊,請參閱這些檔案。接下來,我將把電話會議交給 Align Technology 總裁暨執行長 Joe Hogan。Joe?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Thanks, Shirley. Good afternoon, and thanks for joining us. On our call today, I'll provide some highlights for the first quarter and briefly discuss the performance of our 2 operating segments: clear aligners and intraoral scanners. John will provide more detail on our financial results and discuss our outlook for the second quarter. Following that, I'll come back and summarize a few key points and open up the call to questions.
謝謝,Shirley。各位下午好,感謝各位加入我們。在今天的電話會議中,我將提供第一季的一些重點,並簡要討論我們兩個營運部門的表現:透明牙套與口內掃描器。John 將更詳細說明我們的財務結果,並討論第二季展望。之後我會回來總結幾個關鍵重點,並開放提問。
Our first quarter was a very good start to the year with revenues, volumes, gross margin and EPS all above our guidance. Record Q1 revenues and Invisalign volumes were up 25.6% and 28.3% year-over-year, respectively, reflecting continued strong growth across all geographies and customer channels as well as strong iTero Scanner and services revenues which were up 55.1% year-over-year.
我們第一季為今年帶來非常好的開局,營收、出貨量、毛利率與每股盈餘(EPS)皆高於我們的指引。第一季營收創新高,Invisalign 出貨量分別較去年同期成長 25.6% 與 28.3%,反映各地區與各客戶通路持續強勁成長;同時 iTero 掃描器與服務營收亦表現強勁,較去年同期成長 55.1%。
Q1 sequential growth was driven primarily by North America and EMEA volumes, reflecting strength across the Invisalign product portfolio. We saw a nice uptick in adoption of Invisalign treatment with a record utilization overall as well as expansion of our customer base which totaled 57,000 active doctors worldwide in Q1.
第一季的季增成長主要由北美與 EMEA 的出貨量帶動,反映 Invisalign 產品組合全面走強。我們看到 Invisalign 治療採用率明顯提升,整體使用率創新高,同時客戶基礎持續擴大;第一季全球活躍醫師總數達到 57,000 名。
Now let's turn to the specifics around our first quarter results starting with the Americas region. For the Americas region, Q1 was a solid quarter with Invisalign case volume up 7.1% sequentially and 21.8% year-over-year, reflecting growth in both our orthodontic and GP dentist channels. Q1, we trained 1,700 new Invisalign doctors in the Americas region, of which, 1,400 were North American doctors. On a sequential basis, Q1 Invisalign volume growth reflects record utilization for the Americas region overall driven by North American orthos at 18.3 cases per doctor with good initial adoption of Invisalign mandibular advancement in North America driven by the mid-Q4 launch in the U.S. We also had solid performance from GP dentists with continued momentum from Invisalign Lite and Invisalign Go. Invisalign Go provides a simple pathway for dentists to integrate mild-to-moderate tooth movement into comprehensive care. And it makes it easy for GPs to refer out more complex cases to orthodontics in the network.
現在讓我們聚焦第一季結果的細節,先從美洲地區開始。就美洲地區而言,第一季表現穩健,Invisalign 病例量季增 7.1%、年增 21.8%,反映我們在矯正專科與一般牙醫(GP)通路皆有成長。第一季我們在美洲地區培訓了 1,700 位新的 Invisalign 醫師,其中 1,400 位為北美醫師。以季比來看,第一季 Invisalign 病例量成長反映美洲地區整體使用率創新高,主要由北美矯正專科醫師帶動,每位醫師平均 18.3 例;同時,受惠於我們在美國於第四季中後段推出 Invisalign mandibular advancement(下顎前導)後的良好初期採用,北美表現強勁。我們的一般牙醫通路亦有穩健表現,Invisalign Lite 與 Invisalign Go 的動能持續。Invisalign Go 為牙醫提供一條簡單途徑,將輕度至中度的牙齒移動整合至全面性照護中。同時也讓一般牙醫能更容易把較複雜的病例轉介給網絡中的矯正專科。
Year-over-year, Q1 Invisalign volume growth in the Americas region was driven by continued strength in ortho channel, especially from our high-volume doctors with 25.9% growth as well as an increase of 15.5% from the GP channel. In March, we announced the collaboration with Digital Smile Design, what we call DSD, a leader in holistic and digital dentistry solutions for dental clinics, which features the Invisalign system and iTero Element scanners as the digital solutions of choice for tooth movement and scanning. As part of the cooperation, Align and DSD will deliver dedicated education programs, enable simplified streamlined integration of digital end-to-end workflows into GP practices and offer doctors more opportunities to learn about digital tools and treatment planning support. We also continue to make great progress in Latin America led by Brazil. In Q1, Invisalign volume in Latin America was up significantly year-over-year, reflecting our ongoing investments as we continue to build our business in the region, training over 300 Invisalign doctors during the quarter. Next month, I'll be in Brazil with the executive team hosting a major customer event with more than 200 doctors discussing the future of digital orthodontics, including the science and technology behind both the Invisalign systems as well as our iTero scanners. We'll also have local social media influencers on hand as we kick off our very first Invisalign consumer campaign in Brazil and plan to live stream portions of the event to more than 500 doctors across the region.
以年比來看,美洲地區第一季 Invisalign 病例量成長由矯正專科通路的持續強勁所帶動,尤其是我們高出貨量醫師的成長達 25.9%,以及一般牙醫通路成長 15.5%。3 月,我們宣布與 Digital Smile Design(我們稱為 DSD)合作;DSD 是牙科診所整體性與數位牙科解決方案的領導者,並將 Invisalign 系統與 iTero Element 掃描器作為牙齒移動與掃描的首選數位解決方案。作為合作的一部分,Align 與 DSD 將提供專屬教育計畫,促成數位端到端工作流程在一般牙醫診所中的簡化與順暢整合,並為醫師提供更多機會了解數位工具與治療規劃支援。我們在拉丁美洲也持續取得重大進展,其中以巴西為首。第一季拉丁美洲的 Invisalign 病例量較去年同期大幅成長,反映我們持續在該地區投資並建置業務;本季培訓超過 300 位 Invisalign 醫師。下個月,我將與高階主管團隊前往巴西,主辦一場大型客戶活動,邀請超過 200 位醫師,共同探討數位矯正的未來,包括 Invisalign 系統與 iTero 掃描器背後的科學與技術。我們也將邀請當地社群媒體意見領袖到場,正式啟動我們在巴西的首個 Invisalign 消費者行銷活動,並計畫將活動部分內容進行直播,觸及該地區超過 500 位醫師。
For our international business, Q1 was another good quarter with strong Invisalign volume growth of 38.5% year-over-year, reflecting increased Invisalign utilization and continued expansion of our customer base in both EMEA and Asia Pacific regions. On a sequential basis, international volume was up slightly, reflecting strong growth in the EMEA region and offset somewhat by a seasonally lower period in Asia Pacific as expected.
就國際業務而言,第一季再度繳出佳績,Invisalign 病例量較去年同期強勁成長 38.5%,反映 EMEA 與亞太兩大區域的 Invisalign 使用率提升,以及客戶基礎持續擴大。以季比來看,國際病例量小幅成長,反映 EMEA 地區強勁成長,但部分被亞太地區如預期的季節性淡季所抵銷。
In Q1, we trained over 2,400 new Invisalign doctors internationally, split roughly between each of the 2 regions. In EMEA, Q1 was a strong quarter with volumes up 37.4% year-over-year driven by growth across the region with record Invisalign volumes in all but one country led by Iberia and France. We saw strength across the Invisalign product portfolio with continued momentum from Invisalign First and Invisalign Go. We also continue to see strong growth across our key expansion markets as well as led by the Nordics and Benelux.
第一季我們在國際市場培訓了超過 2,400 位新的 Invisalign 醫師,兩個區域的占比大致各半。在 EMEA,第一季表現強勁,病例量較去年同期成長 37.4%,由全區域成長所帶動;除一個國家外,其餘各國 Invisalign 病例量皆創新高,其中以伊比利亞與法國領先。我們看到 Invisalign 產品組合全面走強,Invisalign First 與 Invisalign Go 的動能持續。我們也持續看到關鍵擴張市場的強勁成長,其中以北歐與比荷盧地區(Benelux)為首。
For APAC, Q1 Invisalign volume increased 40.4% year-over-year, reflecting continued strong growth from nearly all country markets led by China, Japan and ANZ. We also had a strong uptick in teenage patients in Q1 due in part to a teen promotion in China offered along with our teen edge sales program, intended to increase adoption of Invisalign treatment with teenagers. We also had strong growth from GP dentists, which were up 63.5% year-over-year. On a sequential basis, Q1 was flat as expected due primarily to a seasonally lower period with the lunar new year holiday. During Q1, we trained nearly 1,100 new doctors in APAC, over half of which were in China. We opened our second state-of-the-art training facility in China located in Shanghai. Our new manufacturing facility in Ziyang, China is continuing to ramp. And while we are making good progress, we still expect it to take a couple of quarters to fully transition aligner fabrication from Juarez, Mexico to Ziyang, China to serve the Chinese market and expect manufacturing overhead in Ziyang to be underutilized during this transition period.
在亞太地區(APAC),第一季 Invisalign 出貨量年增 40.4%,反映幾乎所有國家市場持續強勁成長,其中以中國、日本與澳紐(ANZ)領先。第一季青少年患者也明顯增加,部分原因是我們在中國推出青少年促銷活動,並搭配青少年 edge 銷售計畫,旨在提升青少年對 Invisalign 治療的採用率。我們來自一般牙醫(GP)的成長同樣強勁,年增 63.5%。以季比來看,第一季如預期持平,主要因農曆新年假期使該季屬於季節性較淡的期間。第一季期間,我們在亞太訓練了近 1,100 位新醫師,其中超過一半在中國。我們在中國上海開設了第二座最先進的訓練中心。我們在中國資陽的新製造工廠持續爬坡增產。雖然我們進展良好,但我們仍預期需要再花幾個季度,才能將矯正器製作從墨西哥華雷斯(Juarez)完全轉移至中國資陽,以服務中國市場;並預期在此轉移期間,資陽的製造間接成本將因產能利用不足而偏高。
Overall for the teen market in Q1, nearly 100,000 teenagers started treatment with Invisalign clear aligners, an increase of 41.1% year-over-year driven by continued strong adoption across all major regions, especially in APAC and EMEA regions. For Q1, year-over-year Invisalign Teen patient growth for North American orthodontists increased 29.2% and international doctors were up 67.2%. Invisalign First and Invisalign treatment with mandibular advancement continue to ramp globally and are helping to increase our share of teenagers and younger patients worldwide. Overall, we're pleased to see that the use of Invisalign Teen treatment among teenagers continues to outpace adults and that Invisalign First is driving a really strong growth in the kid/tweens segment. We'll continue to drive utilization and growth in our Americas teen business this year with a first Invisalign Teen summit in July. We know that summits increase engagement in Invisalign adoption. So for the first time, we're focusing a summit program completely on teen treatment and teen culture, including a tie-in to 2019 VidCon, the top teen culture and community event. Teen summit is designed to turn low teen submitters into high teens submitters by combining Invisalign specific clinical practice how-tos with an immersive teen culture experience.
整體而言,第一季青少年市場中,近 100,000 名青少年開始使用 Invisalign 透明矯正器治療,年增 41.1%,主要由各大區域持續強勁採用所帶動,尤其是亞太與歐洲、中東及非洲(EMEA)地區。第一季,北美矯正專科醫師的 Invisalign Teen 患者年增 29.2%,國際醫師則年增 67.2%。Invisalign First 與具下顎前移(mandibular advancement)功能的 Invisalign 治療持續在全球加速推進,並有助於提升我們在全球青少年與更年幼患者中的市占率。整體而言,我們樂見青少年使用 Invisalign Teen 治療的增速持續超越成人,而 Invisalign First 正在兒童/學齡前後(kid/tweens)族群帶動非常強勁的成長。今年我們將於 7 月舉辦首屆 Invisalign Teen 高峰會,持續推動美洲地區青少年業務的使用率與成長。我們知道高峰會能提升對 Invisalign 採用的參與度。因此,我們首次將高峰會計畫完全聚焦於青少年治療與青少年文化,並與 2019 VidCon(最具代表性的青少年文化與社群活動)進行連結。青少年高峰會旨在透過結合 Invisalign 專屬臨床實務操作教學與沉浸式青少年文化體驗,將低量青少年病例提交者轉化為高量提交者。
Our consumer marketing efforts are designed to build a category and drive demand for Invisalign treatment through a doctor's office. We invest over $100 million each year in consumer marketing programs, including TV, digital and social media, PR, event marketing and our patient concierge service. Our goals are to make the Invisalign brand a household name worldwide and to motivate consumers to seek Invisalign treatment through a doctor's office. In Q1, we continue to see strong digital engagement with consumers reaching nearly 4 million unique visitors on invisalign.com sites worldwide for a total of 53 million visitors to date. Other key metrics show increased activity and engagement with the Invisalign brand are included in our Q1 quarterly slides.
我們的消費者行銷工作旨在建立品類,並透過醫師診所推動 Invisalign 治療需求。我們每年在消費者行銷計畫上的投資超過 1 億美元,涵蓋電視、數位與社群媒體、公關、活動行銷以及我們的患者禮賓(concierge)服務。我們的目標是讓 Invisalign 品牌在全球成為家喻戶曉的名稱,並促使消費者透過醫師診所尋求 Invisalign 治療。第一季,我們持續看到強勁的數位互動,全球 invisalign.com 網站的獨立訪客接近 400 萬人,累計訪客總數至今達 5,300 萬人次。其他關鍵指標顯示 Invisalign 品牌活動與互動提升,相關內容已納入我們第一季季度簡報投影片中。
In March, we launched a new online tool called SmileView at the International Dental Show, IDS, in Cologne, Germany. SmileView is designed to help prospective Invisalign patients visualize a new, straighter smile before they opt for Invisalign treatment. Within 60 seconds of taking a small selfie using a SmileView online tool with their smartphone or tablet, prospective patients can see what their new smile and straighter teeth may look like with their own facial features. SmileView is available online or in GP practices in beta testing in the U.K. and the U.S., and we are getting really positive feedback.
3 月,我們在德國科隆舉辦的國際牙科展(IDS)上推出一款名為 SmileView 的新線上工具。SmileView 旨在協助潛在 Invisalign 患者在選擇 Invisalign 治療前,先行視覺化呈現更整齊的新笑容。只要使用智慧型手機或平板,透過 SmileView 線上工具拍攝一張簡單自拍,60 秒內潛在患者即可依其自身臉部特徵,看到新笑容與更整齊牙齒可能呈現的樣貌。SmileView 目前可在線上使用,或在英國與美國的一般牙科診所(GP)以 Beta 測試方式提供,我們收到非常正面的回饋。
In North America, we continue to invest in strong digital plans for adults and teens. Our teen-focused content, developed by AwesomenessTV, the fastest-growing youth channel, and teen influencer program help strengthen our brand presence among teens and parents, making Invisalign relevant and fun. During South by Southwest, we reached adult consumers with an immersive experience with the RealSelf: House of Modern Beauty where consumers can learn more about Invisalign and see a simulation of their future smile using Invisalign SmileView technology. And Invisalign was voted by consumers as a most worth it treatment, continuing to demonstrate continued strength with consumers. In EMEA, we held a recruitment drive for our influencer program called Invisalign Smile Squad, generating over 100-plus new influencer applications and 350-plus doctor registrations to take part in the program. And our parent of the teen campaign went live in the U.K. and France, raising awareness amongst a new consumer audience. Q2 will see a launch of our revised patient journey with media campaign strategy for focused markets, better integrating new conversion tools like SmileView and Concierge into the journey.
在北美,我們持續投入強而有力的成人與青少年數位行銷計畫。我們以青少年為主的內容由成長最快的青少年頻道 AwesomenessTV 製作,並透過青少年網紅計畫,強化我們在青少年與家長間的品牌能見度,使 Invisalign 更具相關性且更有趣。在西南偏南(South by Southwest)期間,我們透過 RealSelf:House of Modern Beauty 的沉浸式體驗觸及成人消費者,讓消費者能更了解 Invisalign,並使用 Invisalign SmileView 技術模擬其未來笑容。此外,Invisalign 也被消費者票選為「最值得」的治療之一,持續展現我們在消費者端的強勁實力。在 EMEA,我們為名為 Invisalign Smile Squad 的網紅計畫進行招募活動,產生超過 100 份新的網紅申請,以及超過 350 位醫師註冊參與該計畫。同時,我們的「青少年家長」行銷活動已在英國與法國上線,提升新消費者族群的認知。第二季將推出我們修訂後的患者旅程與聚焦市場的媒體活動策略,更好地將 SmileView 與 Concierge 等新轉換工具整合進旅程中。
In APAC, we continue to build awareness for Invisalign treatment through the use of paid media and influencer campaign, including expansion of our influencer program in the region and a pilot Invisalign First social media campaign to target parents of younger children. To leverage increasing consumer awareness and demand, we also began to expand the Invisalign Concierge program that connects interested consumers with Invisalign doctors for treatment in new countries. Globally, in the second half of the year, we will launch a new consumer advertising campaign that emphasizes the importance of doctor-led treatment with Invisalign clear aligners while also differentiating our brand. On the professional marketing side, we recently launched 2 dedicated professional Invisalign brand campaigns that feature orthodontists and GP dentists. As the "ortho as hero" campaign focuses on Invisalign orthodontists as clinical leaders and the heroes of transformative, life-changing smiles, especially for teen and younger patients. The campaign showcases modern orthodontic practices that leverage digital approaches to treatment and are warm and inviting. The "go beyond" campaign is designed to celebrate dentists who go above and beyond every day to serve their patients. It also demonstrates the relevance of tooth movement to general dentists and the importance of integrating Invisalign with comprehensive dentistry. This was launched in North America and is now being rolled out in EMEA and APAC regions.
在亞太地區,我們持續透過付費媒體與網紅行銷活動提升 Invisalign 治療的認知度,包括擴大區域內的網紅計畫,以及試行 Invisalign First 社群媒體活動以鎖定年幼兒童的家長。為了掌握日益提升的消費者認知與需求,我們也開始在更多新國家擴展 Invisalign Concierge 計畫,將有興趣的消費者與 Invisalign 醫師連結以進行治療。在全球範圍內,我們將於下半年推出新的消費者廣告活動,強調由醫師主導的 Invisalign 透明矯正器治療的重要性,同時凸顯我們品牌的差異化。在專業行銷方面,我們近期推出 2 個專屬的專業端 Invisalign 品牌活動,主角為矯正專科醫師與一般牙醫(GP)。其中「ortho as hero」活動聚焦 Invisalign 矯正專科醫師作為臨床領導者,以及帶來轉變、改變人生笑容的英雄,特別是針對青少年與更年幼患者。該活動展示運用數位化治療方式的現代矯正診所,氛圍溫暖且具吸引力。「go beyond」活動旨在表揚每天為服務患者而超越自我的牙醫師。它也展現牙齒移動對一般牙醫的相關性,以及將 Invisalign 與全口/全方位牙科(comprehensive dentistry)整合的重要性。該活動已在北美推出,現正擴展至 EMEA 與亞太地區。
For our iTero scanner and services business, iTero revenues increased 55.1% year-over-year, reflecting continued strength across all regions and customer channels. On a sequential basis, revenues were down 9.8% sequentially, as expected, reflecting lower scanner sales following a strong Q4 and consistent with the seasonality in the capital equipment business, partially offset by continued growth in services revenues due to the increasing installed base. During the quarter, we launched the new iTero Element 5D imaging system for comprehensive preventive and restorative oral care at the International Dental Show. The iTero Element 5D scanner is the first integrated dental imaging system that simultaneously records 3D, intraoral color and NIRI images, or near-infrared images, and enables comparison over time using iTero TimeLapse. Integrated 3D, intraoral color and NIRI technology of the new iTero 5D imaging system aids in detection and monitoring of interproximal caries lesions above the gingiva without using harmful radiation. The iTero Element 5D Scanner is available for sale in the majority of European and APAC countries and is not yet available in the United States or Latin America. Cumulatively, 13.5 million orthodontic scans and 3.6 million restorative scans have started with iTero scanners. Use of the iTero scanners for Invisalign case submissions continues to grow and remains a positive catalyst for Invisalign utilization. For Q1, total Invisalign cases submitted with the digital scanner in the Americas increased 76% from -- to 76% from 67.3%. In Q1 last year, international scans increased to 59.3%, up from 43.5% in the same quarter last year. Within the Americas, 91.2% of cases submitted by North American orthos were submitted digitally. And China remains at 45% for the quarter. We continue to anticipate that in another year or 2, nearly all Invisalign cases will be submitted digitally, primarily through an iTero scanner.
就我們的 iTero 掃描器與服務業務而言,iTero 營收年增 55.1%,反映各地區與各客戶通路持續強勁的表現。以季比來看,營收季減 9.8%,符合預期,反映在強勁的第四季之後掃描器銷售下滑,且與資本設備業務的季節性一致;但由於裝機基數持續增加帶動服務營收成長,部分抵銷了上述影響。本季我們在國際牙科展推出全新的 iTero Element 5D 影像系統,用於全面性的預防與修復口腔照護。iTero Element 5D 掃描器是第一套整合式牙科影像系統,可同時記錄 3D、口內彩色與 NIRI 影像(即近紅外線影像),並可透過 iTero TimeLapse 進行跨時間的比較。新款 iTero 5D 影像系統整合的 3D、口內彩色與 NIRI 技術,有助於在不使用有害輻射的情況下,偵測並監測牙齦上方的鄰接面齲齒病灶。iTero Element 5D 掃描器已在多數歐洲與亞太國家上市銷售,但尚未在美國或拉丁美洲上市。累計而言,已有 1,350 萬次矯正掃描與 360 萬次修復掃描由 iTero 掃描器啟動。使用 iTero 掃描器提交 Invisalign 病例的情況持續成長,並仍是推動 Invisalign 使用量的正向催化因素。第一季,美洲地區以數位掃描器提交的 Invisalign 病例占比提升至 76%,高於 67.3%。去年第一季,國際地區掃描占比提升至 59.3%,高於去年同期的 43.5%。在美洲地區,北美矯正醫師提交的病例中有 91.2% 以數位方式提交。而中國本季仍維持在 45%。我們仍預期在未來 1 到 2 年內,幾乎所有 Invisalign 病例都將以數位方式提交,主要透過 iTero 掃描器。
Given our continued progress and increased use of digital scans for Invisalign case submission, we continue to get questions regarding interoperability with third-party scanners. With recent product introductions, we want to make sure we are clear about which scanners are not qualified to submit Invisalign case submissions. We developed an interoperability matrix that has been distributed to our sales and customer-facing teams to help inform doctors. It also included our Q1 '19 conference call slides. So please reference it for more detail. However, to ensure there's no confusion in the marketplace, let me quickly reiterate our interoperability position on this call with 2 new scanners, the TRIOS 4 and Primescan. Regarding the TRIOS 4, Align will not qualify TRIOS 4 for any future 3Shape scanner -- or any future 3Shape scanning product for Invisalign interoperability in the U.S. or globally. Regarding Primescan, Align has received a request from Dentsply Sirona to evaluate Primescan for Invisalign case submission and we are considering that request. Until we make a decision to move forward and can conduct testing, Primescan is not qualified for Invisalign case submissions.
鑑於我們持續取得進展,且以數位掃描提交 Invisalign 病例的使用率提高,我們持續收到關於與第三方掃描器互通性的提問。隨著近期產品推出,我們希望清楚說明哪些掃描器不具備提交 Invisalign 病例的資格。我們制定了一份互通性矩陣,已分發給我們的銷售與面向客戶的團隊,以協助向醫師提供資訊。該矩陣也包含在我們 2019 年第一季電話會議簡報中。因此,請參考該資料以取得更多細節。不過,為確保市場上不致產生混淆,讓我在本次電話會議中就兩款新掃描器 TRIOS 4 與 Primescan,快速重申我們的互通性立場。關於 TRIOS 4,Align 將不會在美國或全球範圍內,認證 TRIOS 4 以及任何未來的 3Shape 掃描器或任何未來的 3Shape 掃描產品可用於 Invisalign 互通性。關於 Primescan,Align 已收到 Dentsply Sirona 的請求,要求評估 Primescan 用於提交 Invisalign 病例,我們正在考慮該請求。在我們做出推進決定並完成測試之前,Primescan 不具備提交 Invisalign 病例的資格。
Before I turn the call over to John, I want to update you on 2 other important topics. Our plans to reorganize Align's corporate entity structure to better align with the growing international nature of our business and the recent settlement agreement with Straumann. First, our plans to reorganize our corporate entity structure. Given the rapid expansion of our business globally, we must continue to scale and optimize our operations to help support our growth and financial profile. In March, we announced internally that we would be marking -- making changes to our EMEA headquarters located in Amsterdam in the Netherlands. Specifically, we'd relocate our current EMEA headquarters and move the majority of our corporate functions, finance, IT, HR, legal and our regional EMEA marketing from Amsterdam to Switzerland. We'll begin the transition to the new headquarter location midyear and expect to complete it in 2020. Early. We'll maintain an Amsterdam office to support local commercial operations. In addition, in August, we'll be relocating our current order acquisition, or OA, facility from Amsterdam to Poland to create a centralized operational hub for EMEA, co-located with our new treatment planning facility that we just opened. This new hub in Poland will include iTero business operations, customer success and clinical support teams and IT operations. As we evaluated our options, relocating our EMEA headquarters to Switzerland quickly became our top choice on many factors, including a more favorable and stable operating environment, an opportunity to accelerate our transition to a more decentralized commercial structure for EMEA that reflects the localization we've been working toward, a more centralized geographic location in Europe within EMEA's largest potential market and available talent pool to support key strategic roles required in the new EMEA headquarters. While we expect these proposed changes will allow us to obtain financial and operational efficiencies, it was a difficult decision to make and we're committed to supporting our impacted employees throughout this transition.
在我把電話交給 John 之前,我想向各位更新另外兩個重要主題:我們計畫重整 Align 的公司法人實體架構,以更貼合我們業務日益國際化的特性,以及近期與 Straumann 的和解協議。首先是我們重整公司法人實體架構的計畫。鑑於我們業務在全球快速擴張,我們必須持續擴大規模並優化營運,以支援我們的成長與財務表現。3 月,我們在內部宣布,我們將對位於荷蘭阿姆斯特丹的 EMEA 總部進行變更。具體而言,我們將遷移現有 EMEA 總部,並把大部分公司職能——財務、IT、人資、法務以及 EMEA 區域行銷——從阿姆斯特丹移至瑞士。我們將於年中開始轉移至新的總部地點,並預期在 2020 年完成。在此期間,我們將保留阿姆斯特丹辦公室,以支援當地商業營運。此外,我們將於 8 月把目前的訂單取得(order acquisition,或 OA)設施從阿姆斯特丹遷至波蘭,以建立 EMEA 的集中式營運樞紐,並與我們剛啟用的新治療規劃設施同址。這個位於波蘭的新樞紐將包含 iTero 業務營運、客戶成功與臨床支援團隊,以及 IT 營運。在評估各項選擇時,將 EMEA 總部遷至瑞士很快成為我們在多項因素上的首選,包括更有利且更穩定的營運環境、加速我們向更分散式的 EMEA 商業架構轉型的機會(以反映我們一直努力推動的在地化)、在歐洲更居中的地理位置(位於 EMEA 最大的潛在市場之內),以及可用的人才庫以支援新 EMEA 總部所需的關鍵策略職務。雖然我們預期這些擬議變更將使我們取得財務與營運效率,但這是一項艱難的決定;我們承諾在整個轉型期間支持受影響的員工。
Moving onto the settlement with Straumann. On March 28, we announced a settlement with the Straumann group to settle patent disputes with ClearCorrect who was purchased by Straumann in 2017. As many of you know, for years, Align has been engaged in complicated, multi-country, multi-court patent litigation with ClearCorrect. The settlement with Straumann ends all current and pending litigation, provides $35 million in settlement fees to Align. In addition, we've signed a nonbinding letter of intent, LOI, with Straumann for an iTero development and distribution agreement. If we reach an agreement, Straumann will purchase and distribute 5,000 iTero scanners over the next 5 years and co-fund development with us to integrate Straumann's digital workflow into those scanners. The letter of intent we've signed is nonbinding, which means either one of us can walk away from the LOI. However, if we don't reach a development and distribution agreement with Straumann by early July, Straumann will pay us an additional $16 million for a total of $51 million. We have always been passionate about defending our intellectual property and the hard work and innovation by the Align team that it represents. We will continue to do that and to protect our technology through all the ways that our legal system provides. With that, I'll now turn the call over to John.
接著談與 Straumann 的和解。3 月 28 日,我們宣布與 Straumann 集團達成和解,以解決與 ClearCorrect 的專利爭議;ClearCorrect 於 2017 年被 Straumann 收購。如各位所知,多年來 Align 一直與 ClearCorrect 進行複雜的跨國、跨法院專利訴訟。與 Straumann 的和解終結所有現行及待決訴訟,並向 Align 提供 3,500 萬美元的和解金。此外,我們已與 Straumann 簽署一份不具約束力的意向書(LOI),內容為 iTero 的開發與經銷協議。若我們達成協議,Straumann 將在未來 5 年內採購並經銷 5,000 台 iTero 掃描器,並與我們共同出資開發,以將 Straumann 的數位工作流程整合至這些掃描器中。我們所簽署的意向書不具約束力,這表示任何一方都可以退出該 LOI。然而,若我們在 7 月初之前未能與 Straumann 達成開發與經銷協議,Straumann 將額外支付我們 1,600 萬美元,使總額達到 5,100 萬美元。我們一向致力於捍衛我們的智慧財產權,以及其所代表的 Align 團隊的辛勤工作與創新。我們將持續如此,並透過法律制度所提供的一切方式保護我們的技術。接下來,我將把電話交給 John。
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
Thanks, Joe. Now for our Q1 financial results. Total revenue for the first quarter was $549 million, up 2.8% from the prior quarter and up 25.6% from the corresponding quarter a year ago. Year-over-year revenue growth includes $16.5 million of unfavorable foreign exchange. For clear aligners, Q1 revenue of $469.2 million was up 5.3% sequentially on strong Invisalign volume from North America and EMEA and higher-than-expected Invisalign ASPs. Year-over-year clear aligner revenue growth of 21.7% reflected strong Invisalign shipment growth across all customer channels and geographies. Q1 Invisalign ASPs were up sequentially by approximately $10 to $1,245, reflecting favorable impacts from FX and product mix shift, partially offset by higher promotions. On a year-over-year basis, Q1 Invisalign ASPs were down $65, primarily reflecting promotional discounts, unfavorable foreign exchange and product mix shift, partially offset by price increases in July 2018.
謝謝你,Joe。接下來說明我們第一季(Q1)的財務結果。第一季總營收為5.49億美元,較前一季成長2.8%,較去年同期成長25.6%。年增營收成長包含1,650萬美元的不利匯率影響。就透明牙套而言,Q1營收為4.692億美元,受北美與EMEA地區Invisalign出貨量強勁以及高於預期的Invisalign平均售價(ASP)帶動,較前一季成長5.3%。透明牙套營收年增21.7%,反映Invisalign在所有客戶通路與各地區的出貨成長強勁。Q1 Invisalign ASP較前一季約增加10美元至1,245美元,反映匯率與產品組合轉移的有利影響,部分被較高的促銷所抵銷。以年對年來看,Q1 Invisalign ASP下降65美元,主要反映促銷折扣、不利匯率與產品組合轉移,部分被2018年7月的漲價所抵銷。
Total Q1 Invisalign shipments of 349,200 cases were up 4.6% sequentially and up 28.3% year-over-year. For America's orthodontists, Q1 Invisalign case volume was up 9.5% sequentially and up 25.9% year-over-year. For America's GP dentists, Invisalign case volume was up 3.5% sequentially and up 15.5% year-over-year. For international doctors, Invisalign case volume was up 1.3% sequentially and up 38.5% year-over-year. Our scanner and services revenue for the first quarter was $79.8 million, down 9.8% sequentially due to seasonality as Q4 is typically stronger due to end of year capital equipment purchases. Year-over-year revenue was up 55.1%, primarily due to higher scanner units across regions and related service revenues.
Q1 Invisalign總出貨量為349,200例,較前一季成長4.6%,較去年同期成長28.3%。就美洲的矯正專科醫師而言,Q1 Invisalign病例量較前一季成長9.5%,較去年同期成長25.9%。就美洲的一般牙醫(GP)而言,Invisalign病例量較前一季成長3.5%,較去年同期成長15.5%。就國際醫師而言,Invisalign病例量較前一季成長1.3%,較去年同期成長38.5%。第一季掃描儀與服務營收為7,980萬美元,因季節性因素較前一季下降9.8%,因第四季通常因年末資本設備採購而較強。年對年營收成長55.1%,主要由於各地區掃描儀出貨台數增加及相關服務營收提升。
Moving on to gross margin. First quarter overall gross margin was 73.2%, up 1.5 points sequentially and down a 1.7 points year-over-year. Clear aligner gross margin for the first quarter was 74.9%, up 0.8 points sequentially, primarily due to improved manufacturing leverage, approximately $4 million of onetime benefits related to freight refunds and rebates, and seasonally lower training costs, partially offset by higher number of aligners per case. Clear aligner gross margin was down 2.1 points year-over-year, primarily due to higher number of aligners per case, lower ASPs, partially offset by favorable manufacturing leverage and onetime benefits related to freight refunds and rebates as described above along with lower doctor training costs. Scanner gross margin for the first quarter was 63.6%, up 3.7 points sequentially and up 4.4 points year-over-year, primarily due to higher ASPs and onetime benefits related to freight refunds along with manufacturing efficiencies.
接著談毛利率。第一季整體毛利率為73.2%,較前一季上升1.5個百分點,較去年同期下降1.7個百分點。第一季透明牙套毛利率為74.9%,較前一季上升0.8個百分點,主要由於製造規模效益改善、約400萬美元與運費退款及回扣相關的一次性利益,以及季節性較低的訓練成本,部分被每例牙套片數增加所抵銷。透明牙套毛利率年對年下降2.1個百分點,主要由於每例牙套片數增加與ASP下降,部分被有利的製造規模效益及上述與運費退款與回扣相關的一次性利益,以及較低的醫師訓練成本所抵銷。第一季掃描儀毛利率為63.6%,較前一季上升3.7個百分點,較去年同期上升4.4個百分點,主要由於ASP提高、與運費退款相關的一次性利益,以及製造效率提升。
Q1 operating expenses were $314.4 million, up sequentially 19.7% and up 37.2% year-over-year. The sequential increase in operating expenses reflects continued investment in sales and R&D activities along with higher legal-consulting expenses as well as increased compensation related to expenses due to higher headcount and our planned annual increase in employee compensation programs, partially offset by seasonally lower advertising spending. Additionally, our Q1 operating expenses include the impairments and other charges related to Invisalign store closures of $29.8 million.
Q1營業費用為3.144億美元,較前一季增加19.7%,較去年同期增加37.2%。營業費用的季增主要反映我們持續投資於銷售與研發活動,以及較高的法律與顧問費用,並因員工人數增加與我們規劃的年度員工薪酬方案調升而使薪酬相關費用增加;部分被季節性較低的廣告支出所抵銷。此外,我們Q1營業費用包含與Invisalign門市關閉相關的減損及其他費用2,980萬美元。
Our first quarter operating income was $87.7 million, down 27.2% sequentially and down 10.7% year-over-year. The sequential decrease in operating income is primarily attributed to higher operating expenses, offset in part by higher gross profit. On a year-over-year basis, the decrease in operating income primarily reflects higher operating expenses commensurate from growth, which includes charges related to our Invisalign store closures. Our first quarter operating margin was 16%, down 6.6 points sequentially and down 6.5 points year-over-year. The sequential decrease in operating margin is primarily due to higher operating expenses and the Invisalign store closure costs, partially offset by higher gross margin. The year-over-year decrease in operating margin is primarily due to higher operating expenses and Invisalign store closure costs and lower gross margin. The Q1 operating margin impact from the store closures was approximately 540 basis points.
第一季營業利益為8,770萬美元,較前一季下降27.2%,較去年同期下降10.7%。營業利益的季減主要歸因於營業費用增加,部分被較高的毛利所抵銷。以年對年來看,營業利益下降主要反映隨成長而增加的營業費用,其中包含與Invisalign門市關閉相關的費用。第一季營業利益率為16%,較前一季下降6.6個百分點,較去年同期下降6.5個百分點。營業利益率的季減主要由於營業費用增加及Invisalign門市關閉成本,部分被較高的毛利率所抵銷。營業利益率的年減主要由於營業費用增加、Invisalign門市關閉成本以及較低的毛利率。門市關閉對Q1營業利益率的影響約為540個基點。
With regards to the first quarter tax provision. Our tax rate was 10.4%, which includes approximately $12 million of excess tax benefit related to stock-based compensation from restricted stock vesting during the quarter and approximately $8 million of discrete tax benefit related to the tax impact of the Invisalign store closure costs. First quarter diluted earnings per share was $0.89, down $0.31 sequentially and down $0.28 compared to the prior year. Invisalign store related closure costs, net of tax, impacted Q1 diluted earnings per share by approximately $0.28.
關於第一季所得稅費用。我們的有效稅率為10.4%,其中包含約1,200萬美元與本季限制性股票歸屬所產生之以股票為基礎之薪酬相關的超額稅務利益,以及約800萬美元與Invisalign門市關閉成本之稅務影響相關的一次性稅務利益。第一季稀釋後每股盈餘為0.89美元,較前一季下降0.31美元,較去年同期下降0.28美元。Invisalign門市相關關閉成本(稅後)對Q1稀釋後每股盈餘的影響約為0.28美元。
Moving on to the balance sheet. As of March 31, 2019, cash, cash equivalents and marketable securities, including both short- and long-term investments, were $732.5 million, a decrease of $11.9 million from the prior quarter, which is primarily from $50 million used to repurchase approximately 205,000 shares of our stock. Of the $732.5 million of cash, cash equivalents and marketable securities, $372.6 million was held in the U.S. and at $359.9 million was held by our international entities. Q1 accounts receivable balance was $479.3 million, up approximately 9.2% sequentially. Our overall days sales outstanding was 78 days, up 4 days sequentially and up 4 days from Q1 last year. Cash flow from operations for the first quarter was $117.2 million, up $39.9 million compared to the prior year.
接著看資產負債表。截至2019年3月31日,現金、約當現金及有價證券(包含短期與長期投資)為7.325億美元,較前一季減少1,190萬美元,主要因我們使用5,000萬美元回購約205,000股公司股票。在7.325億美元的現金、約當現金及有價證券中,3.726億美元持有於美國,3.599億美元由我們的海外實體持有。Q1應收帳款餘額為4.793億美元,較前一季約增加9.2%。整體應收帳款週轉天數(DSO)為78天,較前一季增加4天,較去年Q1增加4天。第一季營運活動現金流量為1.172億美元,較去年同期增加3,990萬美元。
Capital expenditures for the first quarter were $35.3 million, primarily related to our continued investment in increasing aligner capacity and facilities. Free cash flow for the first quarter, defined as cash flow from operations less capital expenditures, amounted to $81.9 million.
第一季資本支出為3,530萬美元,主要與我們持續投資以提升牙套產能與設施相關。第一季自由現金流量(定義為營運活動現金流量減資本支出)為8,190萬美元。
During Q1, we repurchased on the open market approximately 200,000 shares of our common stock at an average price of $243.42 per share, including commission, for the aggregate purchase price of approximately $50 million. We have $450 million remaining available for repurchase under the May 2018 repurchase program. Also during the first quarter, we adopted the new lease standard and now record operating leases, lease assets and related liabilities on our consolidated balance sheet. However, there was no significant impact to our operating results.
在Q1期間,我們於公開市場以每股平均243.42美元的價格回購約200,000股普通股(含手續費),總買回金額約5,000萬美元。在2018年5月的回購計畫下,我們仍有4.5億美元可用於回購。此外,在第一季我們採用新的租賃準則,並於合併資產負債表上認列營業租賃、租賃資產及相關負債。然而,對我們的營運結果並無重大影響。
With that, let's turn to our Q2 outlook and the factors that inform our view, starting with the demand outlook. For international, we expect Q2 volumes to be up sequentially, reflecting seasonally stronger periods for both EMEA and APAC regions. For Americas, we expect Q2 volumes to be up sequentially, reflecting growth across all key markets as well as seasonally stronger period for North America orthodontists with the beginning of the summer teen season. We expect our iTero business to be up sequentially coming off a slower period for capital equipment in Q1. And regarding SmileDirectClub, we expect almost no clear aligner volume from SDC in Q2. With this as a backdrop, we expect the second quarter to shape up as follows. Invisalign case volume is expected to be in the range of 380,000 to 385,000 cases, up approximately 26% to 27% year-over-year. We expect Q2 revenues to be in the range of $590 million to $600 million, up approximately 20% to 22% year-over-year. Our Q2 revenue outlook assumes almost no SDC volume compared to the same quarter a year ago when aligners supplied to SDC contributed $8.6 million to revenue. We expect Q2 gross margin to be in the range of 71.5% to 72.5%. Q2 gross margin is sequentially lower than Q1 due to the onetime benefits of approximately 1% realized in Q1 that do not -- that we do not expect to repeat. We expect Q2 operating expenses to be in the range of $277 million to $282 million, which includes a onetime benefit of approximately $30 million from the Straumann settlement gain, net of our estimated cost for the iTero development agreement. Q2 operating expenses reflect continued investment in sales, marketing and R&D, including increased consumer media/advertising spend as well as higher legal fees and costs related to our corporate structure reorganization announced last quarter. Q2 operating margin should be in the range of 24.5% to 25.4%, which includes the expected benefit from the Straumann settlement gain mentioned above and approximately 2% negative impact to the operating margin due to higher legal fees and costs related to our corporate structure reorganization.
基於此,讓我們轉向第二季(Q2)的展望,以及支撐我們觀點的因素,先從需求展望談起。就國際市場而言,我們預期Q2出貨量將較前一季成長,反映EMEA與APAC地區季節性較強的期間。就美洲市場而言,我們預期Q2出貨量也將較前一季成長,反映所有主要市場的成長,以及北美矯正醫師在暑期青少年旺季開始時的季節性走強。我們預期iTero業務將較前一季成長,因Q1資本設備需求處於較慢的期間。至於SmileDirectClub,我們預期Q2幾乎不會有來自SDC的透明牙套出貨量。在此背景下,我們預期第二季將呈現如下走勢。Invisalign病例量預期介於38萬至38.5萬例之間,年增約26%至27%。我們預期Q2營收介於5.90億至6.00億美元之間,年增約20%至22%。我們的Q2營收展望假設幾乎沒有SDC出貨量;相較之下,一年前同一季度供應給SDC的牙套為營收貢獻了860萬美元。我們預期Q2毛利率介於71.5%至72.5%。Q2毛利率較Q1按季下降,原因是Q1實現約1%的一次性利益,我們不預期會再度出現。我們預期Q2營業費用介於2.77億至2.82億美元之間,其中包含來自Straumann和解收益約3,000萬美元的一次性利益,並已扣除我們對iTero開發協議的估計成本。Q2營業費用反映我們持續在銷售、行銷與研發上的投資,包括增加消費者媒體/廣告支出,以及與上季宣布的公司架構重組相關的較高法律費用與成本。Q2營業利益率應介於24.5%至25.4%,其中包含上述Straumann和解收益的預期利益,並因公司架構重組相關的較高法律費用與成本,對營業利益率造成約2%的負面影響。
Note, as we described on our Q4 earnings call in January, we expect the impact from higher legal and corporate structure reorganization costs to be about 1.5% to 2% for the full year. Our effective tax rate is expected to be approximately 24%. Diluted shares outstanding is expected to be approximately 80.6 million, exclusive of any share repurchases. Taken together, we expect our Q2 diluted earnings per share to be in the range of $1.47 to $1.54. Q2 diluted earnings per share guidance includes $0.28 gain from the Straumann settlement and $0.10 gain from the SDC equity settlement, net of the income tax effects, and approximately $0.09 expense related to the corporate structure reorganization costs and higher legal/litigation costs. In addition, as we continue our operational expansion efforts, we expect CapEx for Q2 to be approximately $85 million to $90 million, and we expect depreciation and amortization to be $20 million to $22 million. With that, I'll turn it back over to Joe for final comments. Joe?
請注意,如同我們在1月的Q4財報電話會議中所述,我們預期較高的法律費用與公司架構重組成本對全年影響約為1.5%至2%。我們的有效稅率預期約為24%。稀釋後流通在外股數預期約為8,060萬股,不包含任何庫藏股回購。綜合以上,我們預期Q2稀釋後每股盈餘介於1.47美元至1.54美元。Q2稀釋後每股盈餘指引包含:Straumann和解帶來0.28美元收益,以及SDC股權和解帶來0.10美元收益(均已扣除所得稅影響),並包含約0.09美元費用,與公司架構重組成本及較高的法律/訴訟成本相關。此外,隨著我們持續推動營運擴張,我們預期Q2資本支出(CapEx)約為8,500萬至9,000萬美元,折舊與攤銷預期為2,000萬至2,200萬美元。接下來,我把時間交還給Joe做最後評論。Joe?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Thanks, John. Overall, Q1 was another solid quarter, and I'm pleased with the continued progress we're making in executing on our strategic growth drivers and I'm excited about the opportunity we have. I just want to highlight those 4 growth drivers here for the quarter. From an international expansion standpoint, Invisalign volume was up 38.5%. On our ortho/teen utilization, our worldwide Invisalign Teen patient growth was over 41%. GP treat and refer, leading with iTero scanners, our worldwide GP volumes for Invisalign were up 27.3% and 15.5% for GPs in the Americas. And iTero Scanner revenues were up 55%. Consumer and patient conversion with Invisalign treatment, we engaged with 4 million consumers globally in Q1 and are building the most recognized orthodontic brand in the industry. In Q2, we have a number of exciting programs and initiatives heading into the summer season, kicking off with the AAO in early May and the Invisalign symposium on the digital practice in London, which is our first ever truly global event designed to foster a global community of Invisalign doctors. This symposium will bring together 300 of the most experienced and most high volume Invisalign orthodontists from across the world to discuss the digital orthodontics and the challenges and opportunities digital transformation provides for their practices.
謝謝你,John。整體而言,Q1又是一個穩健的季度;我對我們在執行策略性成長驅動因素上持續取得的進展感到滿意,也對我們所擁有的機會感到振奮。我想在此強調本季的4項成長驅動因素。從國際擴張的角度來看,Invisalign出貨量成長了38.5%。在矯正/青少年使用率方面,我們全球Invisalign Teen患者成長超過41%。在GP治療與轉介方面,以iTero掃描器為先導,我們全球GP的Invisalign出貨量成長27.3%,而美洲地區GP成長15.5%。iTero掃描器營收成長55%。在以Invisalign治療帶動的消費者與患者轉換方面,我們在Q1於全球觸及400萬名消費者,並正打造業界最具辨識度的矯正品牌。進入Q2、迎接暑期旺季,我們有多項令人振奮的計畫與倡議,首先是5月初的AAO,以及在倫敦舉辦、聚焦數位診所的Invisalign研討會;這是我們首次真正的全球性活動,旨在促進Invisalign醫師的全球社群。本次研討會將匯聚來自全球300位最資深、病例量最高的Invisalign矯正醫師,共同討論數位矯正,以及數位轉型為其診所帶來的挑戰與機會。
Finally, before I open the call to questions, I want to take a minute to welcome Raj Pudipeddi who joined Align last month as Senior Vice President and Chief Marketing Officer, CMO, reporting to me. Raj joins us with more than 24 years of business leadership experience and brand building experience for companies, including Procter & Gamble and Bharti Airtel, an Indian telecom leader. He has an outstanding track record of delivering results across North America, Latin America and Asia Pacific regions. Raj also brings great consumer acumen and marketing expertise in terms of building brands, launching new products and accelerating digital businesses globally. His knowledge and understanding of how to leverage big data and consumer personalization will be instrumental as we continue to lead a transformation of digital orthodontics and dentistry and help millions of consumers get a smile they love with Invisalign doctors. Raj is a strong addition to our leadership team and I'm thrilled to have him on board.
最後,在我開放提問之前,我想花一點時間歡迎Raj Pudipeddi;他於上個月加入Align,擔任資深副總裁暨行銷長(CMO),向我匯報。Raj擁有超過24年的企業領導與品牌打造經驗,曾任職於寶僑(Procter & Gamble)以及印度電信領導企業Bharti Airtel等公司。他在北美、拉丁美洲與亞太地區皆有卓越的成果交付紀錄。Raj亦具備深厚的消費者洞察與行銷專業,涵蓋品牌建立、新產品上市,以及在全球加速數位業務成長。他在如何運用大數據與消費者個人化方面的知識與理解,將在我們持續引領數位矯正與牙科轉型、並協助數以百萬計的消費者透過Invisalign醫師獲得他們喜愛的笑容之際,發揮關鍵作用。Raj是我們領導團隊的重要補強,我很高興他加入我們。
With that, I want to thank you again for joining our call. I look forward to updating you on our progress as the year unfolds. We'll see many of you at the American Association of Orthodontics meeting in Los Angeles next month as well as the upcoming financial conferences, including Bank of America Merrill Lynch, North Coast, Stifel, Goldman Sachs and William Blair. Now I'll turn the call over to the operator for questions. Operator?
基於此,我再次感謝各位參與本次電話會議。我期待在今年進展推進的過程中,持續向各位更新我們的成果。下個月我們將在洛杉磯舉行的美國矯正醫師協會(American Association of Orthodontics)年會與許多各位見面,也會出席接下來的金融研討會,包括美國銀行美林(Bank of America Merrill Lynch)、North Coast、Stifel、高盛(Goldman Sachs)以及William Blair。現在我把電話交給接線員進行提問。接線員?
Operator
Operator
(Operator Instructions) Our first question is from Erin Wright with Credit Suisse.
(接線員指示) 我們的第一個問題來自瑞士信貸(Credit Suisse)的Erin Wright。
Erin Elizabeth Wilson Wright - Director & Senior Equity Research Analyst
Erin Elizabeth Wilson Wright - Director & Senior Equity Research Analyst
So on the gross margin, how should we be thinking about the run rate for the remainder of the year? I understand there were some onetime factors and freight refunds, rebates. Are there other moving parts we should be thinking about in the second quarter from a gross margin perspective? And more broadly, can you characterize how we should be thinking about that longer-term leverage to that metric over the next few years?
關於毛利率,對於今年剩餘期間的常態水準(run rate),我們應該如何思考?我理解其中有一些一次性因素,以及運費退款、回扣等。從毛利率的角度來看,第二季是否還有其他我們應該留意的變動因素?更廣泛地說,未來幾年在這項指標上較長期的槓桿效應(leverage)應該如何看待?
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
Erin, this is John. Yes, what we saw in Q1, we saw good improvement in our gross margin. We talked about 4 million or so of some of the unusuals. You strip that out, what we expect as we go forward in our Q2 guidance is a progression. We're going to continue to improve our gross margin. Some of that comes to some of the operational efficiencies in China and other places that we'll see as the year progresses.
Erin,我是John。是的,我們在第一季看到的是毛利率有不錯的改善。我們談到大約400萬左右的一些一次性/非經常性項目。把那些剔除之後,依我們對第二季指引的預期,接下來會呈現逐步改善。我們會持續提升毛利率。其中一部分來自中國及其他地區的營運效率提升,這些會隨著年度推進而逐步顯現。
Erin Elizabeth Wilson Wright - Director & Senior Equity Research Analyst
Erin Elizabeth Wilson Wright - Director & Senior Equity Research Analyst
Okay. Great. And then can you speak to some of the incremental cost and opportunities associated with this reorganization of your corporate entity structure? Are there incremental costs there from what you said in the fourth quarter and what are those longer-term financial efficiencies that this can generate from a tax perspective or from an operational perspective as well?
好的。很好。接著,你能談談這次公司法人實體架構重組所帶來的增量成本與相關機會嗎?相較於你們在第四季所說的,是否會有額外的增量成本?另外,從稅務角度或營運角度來看,這項重組長期能帶來哪些財務效率?
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
Yes. Erin, this is John again. So no additional than what we talked about. We laid out from a reorganization standpoint about 1% in total for the year. And that will really progress from Q2 on. But really what we see is a more agile organization and one that can accommodate changes to any global changes that might come up around taxes or anything else. So that's really the benefits that we have. EMEA is growing so much, this centralizes that location but it also gives us an operating structure that we can use in the future.
是的。Erin,我又是John。所以沒有比我們先前談到的更多。從重組的角度,我們已說明全年合計大約是1%。而這會從第二季開始逐步反映。但我們真正看到的是一個更敏捷的組織,能夠因應任何可能出現的全球性變化,例如稅務或其他事項。所以這就是我們的主要效益。EMEA成長非常快,這能把該地區集中化,同時也提供我們一個未來可沿用的營運架構。
Operator
Operator
Our next question is from Jeff Johnson with Baird.
我們的下一個問題來自Baird的Jeff Johnson。
Jeffrey D. Johnson - Senior Research Analyst
Jeffrey D. Johnson - Senior Research Analyst
So let me start with you, Joe, and then I have a question for John as well on the margin front. But Joe, with the store shutdown here in April, I guess, what are you seeing impact-wise on volumes maybe in the near term whether that's 2Q over the next couple of quarters? And then how might that impact how you allocate some expenses this year? Is there some way you can reallocate those expenses into other kind of growth initiatives whether that's with DSOs or other private docs or what have you?
那我先從你開始,Joe,然後我也有一個關於毛利率的問題要問John。不過Joe,四月這次門市關閉,我想問你們在量的影響上目前看到什麼情況?可能是短期、例如第二季或接下來幾季?然後這會如何影響你們今年一些費用的配置?你們是否能把這些費用重新配置到其他成長計畫上,例如與DSO或其他私人診所醫師合作之類的?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
First of all, I mean, I think when we announced this issue with the SDC and having to close the stores, we just said it wasn't going to be material from a revenue standpoint and what we -- for the year. So we're sticking with that overall. I mean obviously, there will be some case lost from a store standpoint. The other part of your question is we shift some of that spend back into advertising back into other activities that we have going on to help to drive that demand. So we are -- we will reallocate that expense. It's reallocated into marketing and sales to be able to do that. And we expect to have the results from that, too. You have, I think, good experience in understanding what that investment return rate is.
首先,我的意思是,我想當我們宣布SDC的這個問題並必須關閉門市時,我們就說過,從營收角度來看,對全年而言不會是重大影響。所以我們整體上仍維持這個看法。當然,從門市端來看,會有一些個案流失。至於你問題的另一部分,我們會把其中一部分支出轉回到廣告,以及我們正在進行的其他活動上,以協助帶動需求。所以我們會——我們將重新配置那筆費用。它會重新配置到行銷與銷售上,以便做到這點。而我們也預期會看到相應的成果。我想你對那類投資報酬率的理解也很有經驗。
Jeffrey D. Johnson - Senior Research Analyst
Jeffrey D. Johnson - Senior Research Analyst
All right. That's helpful. And then, John, on the margin front. I mean if I exclude some of the onetime costs in the 1Q, it seems like your operating margin probably would have beaten by maybe 500 basis points or so relative to your guidance. And then if I take into account the gains in 2Q, it seems like margins are going to be down 400, 500 basis points year-over-year into 2Q which is kind of worse than we were thinking. So I guess I'm just trying to get my arms around kind of volatility around margins. Is there more volatility ex the noise in the base business going on right now? Is there just conservatism in your base business guidance for 2Q? How should we think about kind of recent and future margin trends?
好。這很有幫助。接著,John,關於毛利率。我的意思是,如果我把第一季的一次性成本排除,看起來你們的營業利益率相對於指引可能高出大約500個基點左右。然後如果我把第二季的收益納入考量,看起來第二季的毛利率年對年會下降400到500個基點,這比我們原先想的更差一些。所以我想我只是想更好掌握毛利率的波動性。在排除基礎業務中的雜訊之後,目前是否仍有更多波動?還是說你們對第二季基礎業務指引比較保守?我們應該如何看待近期與未來的毛利率趨勢?
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
Yes. So from a -- you're talking specific gross margin. When you look at that, we're seeing good improvement from some of the manufacturing efficiencies and things that happened in the first quarter. We expect that to continue. We saw ASPs up $10 in Q1, which helps contribute to that. But this is about being able to continue to leverage the manufacturing and the other operations that we have and that should continue to get better as the year progresses. And so that's similar to what we talked about at the end of Q4 as well. This is something that we -- we'll get those efficiencies as the year progresses.
是的。所以從——你講的是具體的毛利率。當你看那個指標時,我們看到第一季一些製造效率提升以及相關事項帶來不錯的改善。我們預期這會持續。我們看到第一季ASP上升了10美元,這也有助於貢獻改善。但重點在於能持續槓桿化我們的製造與其他營運,而隨著年度推進,這些應該會持續變得更好。因此這與我們在第四季末所談的也一致。這是我們——我們會在年度推進中逐步取得這些效率。
Jeffrey D. Johnson - Senior Research Analyst
Jeffrey D. Johnson - Senior Research Analyst
All right. Well, let me just clarify, I guess, that question and focus just on the first quarter. Ex the charges in the 1Q, it seems like your margin probably beat, even at the operating line, by almost 500 basis points relative to your guidance because I think your guidance did not anticipate these onetime store closure costs in that. So what drove that upside? And how did you get the 500 basis points of upside in the quarter?
好。那我想先澄清一下這個問題,並只聚焦在第一季。排除第一季的那些費用後,看起來你們的毛利率,甚至在營業利益率層面,相對於指引可能高出將近500個基點,因為我認為你們的指引並未把這些一次性的門市關閉成本納入。所以是什麼驅動了這個超預期?你們在該季是如何做到多出500個基點的?
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
Yes. So really when we saw as we look through it, Jeff, we saw, I said, some improvement on the gross margin standpoint. Some of the OpEx leverage that we were able to achieve in the first quarter as well. And that started our year in a very strong position from an operating margin standpoint. And then as we go through the year, as we've talked about, there'll be some litigation and some reorganization costs that we've been calling out as we go to it. But it was really a strong start to the year from a gross margin standpoint. And then managing the op expenditures and we saw that leverage really show up in Q1.
是的。所以當我們深入檢視時,Jeff,我們看到的是——如我所說——在毛利率方面有一些改善。同時第一季我們也達成了一些營業費用(OpEx)的槓桿效益。這讓我們在營業利益率的角度,以非常強勁的態勢開啟今年。然後隨著年度推進,如我們所談到的,會有一些訴訟以及重組成本,我們也一直在逐步提示。但主要就是毛利率面向的強勁開局。再加上對營業支出的管理,我們看到那個槓桿效益在第一季確實反映出來。
Operator
Operator
Our next question is from Jon Block with Stifel.
我們的下一個問題來自Stifel的Jon Block。
Jonathan David Block - MD & Senior Equity Research Analyst
Jonathan David Block - MD & Senior Equity Research Analyst
I'm also going to ask a margin-related question and then I'll pivot. But just, John, big normalized EPS beat for 1Q. Obviously, there's been sort of no shortage of news flow in the past couple of months. I just wanted to check and I'm going to drill down or make sure I'm clear on the op margins. In other words, if I were to check in on the 2H '19 op margin, should that get back that 25% to 30% OM range that you alluded to last quarter? That's sort of part A of number one. And then part B would be your 2Q revenue guidance, the revs are slightly ahead with the cases a smidge below. So do we assume a sort of a flattish 1Q to 2Q ASP, and then I'll ask my second one.
我也要先問一個與毛利率相關的問題,然後我會再轉到其他主題。不過,John,第一季標準化EPS大幅超預期。顯然過去幾個月新聞動態很多。我只是想確認一下,並更深入或確保我對營業利益率的理解是清楚的。換句話說,如果我去看2019年下半年(2H '19)的營業利益率,它是否應該回到你們上季提到的25%到30%營業利益率區間?這算是第一個問題的A部分。然後B部分是你們第二季營收指引:營收略高一些,但案件數略低一些。所以我們是否可以假設第一季到第二季的ASP大致持平?然後我再問第二個問題。
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
Okay. Yes. From an op margin standpoint and what we tried to do is lay that out a little bit in the slides for you, Jon. But when we look at -- as we reported on a GAAP basis, just talk to the high guide of 25.4% from a guidance standpoint. And we're staying within there because that's GAAP. Within there is the Straumann settlement of approximately 5 points. And then we have some of the corporate structure and reorganization costs as well as the legal cost. And you back out or add back a couple of points for that. So that gets you to 22.5% from an op margin standpoint in Q2 and an operational basis.
好的。是的。從營業利潤率(op margin)的角度來看,我們嘗試在投影片裡為你稍微整理說明一下,Jon。但當我們看——以我們所揭露的 GAAP 基礎來說,就以指引角度談 25.4% 的高端目標。而我們會維持在那個區間內,因為那是 GAAP。其中包含約 5 個百分點的 Straumann 和解。另外也有一些公司架構與重組成本,以及法律費用。把這些扣除或加回大約幾個百分點。因此,從營業利潤率角度來看,Q2 在營業基礎(operational basis)下會到 22.5%。
Jonathan David Block - MD & Senior Equity Research Analyst
Jonathan David Block - MD & Senior Equity Research Analyst
John, I'm sorry. If I could jump in really quick. I didn't mean 2Q, I meant 2H. Last quarter, you talked about 2H '19 op margins falling back in your long-term guidance range of 25% to 30%. Here we are today. Do you feel high conviction in 2H '19 the op margins are 25% to 30%?
John,不好意思。我可以很快插一句嗎?我不是指 2Q,我是指 2H。上個季度你提到,2H '19 的營業利潤率會回落到你們長期指引區間 25% 到 30% 之內。我們今天在這裡。你對 2H '19 的營業利潤率落在 25% 到 30% 有很高的把握嗎?
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
Yes. In the second half, the conviction that we have and what we expect to have in the second half is consistent. It's the 25% range in the second half of the year.
是的。在下半年,我們的把握以及我們預期在下半年的表現是一致的。今年下半年會在 25% 的區間。
Jonathan David Block - MD & Senior Equity Research Analyst
Jonathan David Block - MD & Senior Equity Research Analyst
Okay. And the implied ASPs for 2Q flattish with 1Q? Is that the correct ballpark to be in?
好的。那 2Q 的隱含 ASP 與 1Q 大致持平?這樣理解的區間是對的嗎?
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
Yes. There's a little bit of FX from 1Q to Q2. But essentially flat.
是的。從 1Q 到 Q2 會有一點匯率(FX)影響。但基本上是持平。
Jonathan David Block - MD & Senior Equity Research Analyst
Jonathan David Block - MD & Senior Equity Research Analyst
Okay. Okay, great. And then for 1Q '19, Simon's EMEA growth rate is now within 300 bps relative to Julie's, which I view is a good thing from a diversification standpoint and congrats to Simon, who I know has been chasing Julie for several years. But I'm just curious how we should think about that going forward, especially with the scanner that's technically newer in China. And Joe, you talked about the teen opportunity in China. We think that, call it closer to parity, Joe, is here to say or is there anything unique in one market or the other teen iGo scanner that can cause APAC to sort of separate again?
好的。好的,很好。另外,針對 1Q '19,Simon 的 EMEA 成長率現在相對於 Julie 的差距在 300 個基點以內;我認為從分散化角度看這是件好事,也恭喜 Simon——我知道他追趕 Julie 已經好幾年了。但我想了解我們未來應該如何看待這件事,尤其是掃描器在中國技術上算是較新的。而且 Joe,你談到中國的青少年(teen)機會。我們是否可以認為——Joe——大致接近持平的狀態會持續下去?還是說某個市場有任何獨特因素,或是 teen iGo 掃描器,可能讓 APAC 再次出現某種程度的分化?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Jon, I think, first of all, you got to take cyclicality into that when you look at China and APAC versus EMEA. EMEA goes around the dark side of the moon right after the second quarter. China has a really strong third quarter like they always do. You get the Lunar New Year in the fourth quarter, you got a stronger EMEA in the first quarter. So I think you can't do this kind of an apples-to-oranges comparison when you look at what Simon did this quarter. So what I would take away from this one is you've got a continuing growth rate in EMEA and continuing penetration rates that are terrific. We still have a great business in APAC from a growth standpoint overall. So I love the competition between those 2. I'm cheering for them both, Jon.
Jon,我想首先,當你比較中國與 APAC 對上 EMEA 時,你必須把景氣循環性(cyclicality)納入考量。EMEA 在第二季之後就會進入淡季。中國第三季一向很強,跟以往一樣。第四季有農曆新年,第一季則是 EMEA 較強。所以我認為,當你看 Simon 這一季的表現時,不能用這種「蘋果比橘子」的方式來比較。因此我會從這次得到的結論是:EMEA 的成長率持續、滲透率也非常出色。而從整體成長角度來看,我們在 APAC 仍然有很好的業務表現。所以我很喜歡這兩者之間的競爭。我兩邊都加油,Jon。
Operator
Operator
Our next question is from Robert Jones with Goldman Sachs.
我們的下一個問題來自高盛(Goldman Sachs)的 Robert Jones。
Nathan Allen Rich - Research Analyst
Nathan Allen Rich - Research Analyst
This is Nathan Rich on for Bob this evening. Maybe just going back to ASP. It looks like you saw a pretty nice step up sequentially in the quarter, mostly on the international side. Can you maybe just talk about what came in better than expectation in the quarter? And then you kind of talked about the 2Q guidance for ASPs to be flat. But it does seem like you're seeing some nice progression there relative to your kind of full year guidance for ASPs to be flat to 4Q of last year. So how should we think about the progression of ASPs going forward over the balance of the year?
今晚由 Nathan Rich 代替 Bob 提問。我想回到 ASP 的問題。看起來你們本季的 ASP 季比有相當不錯的提升,主要來自國際市場。你能否談談本季有哪些表現優於預期?另外你們提到 2Q 對 ASP 的指引是持平。但看起來相較於你們全年指引(ASP 相對去年 4Q 持平),你們的進展似乎不錯。那我們應該如何看待今年剩餘期間 ASP 的走勢?
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
Nate, so this is John. Similar to what we've said in the past where we see better comprehensive cases like we saw, I think, compared to what we had expected driven by mandibular advancement and other products that we have. That was in the teen growth that we saw, the 41%. That all contributes to a higher ASP. That showed up in Q1. And when we think about -- as we're looking forward, take FX out of that, we think that it's pretty balanced. We'll have that -- overall, we'll have good international growth. We have that growth in the comprehensive cases with teens. But then we have the low stage mix shift that we see where the low stage growing faster than our comprehensive cases. But in balance, we think it balances out.
Nate,我是 John。跟我們過去說過的類似,當我們看到更好的綜合病例(comprehensive cases)——我想相較於我們原先預期——主要是由下顎前移(mandibular advancement)以及我們其他產品所帶動。這反映在我們看到的青少年成長,也就是 41%。這些都會推升 ASP。這在 Q1 已經反映出來。而當我們往前看——把匯率(FX)因素拿掉——我們認為整體相當均衡。整體而言,我們會有良好的國際成長。我們也會在青少年的綜合病例上看到成長。但同時我們也看到低階方案(low stage)的組合移轉(mix shift),也就是低階方案成長速度快於我們的綜合病例。不過綜合來看,我們認為會彼此抵銷、維持平衡。
Nathan Allen Rich - Research Analyst
Nathan Allen Rich - Research Analyst
Okay. That makes sense. And then, Joe, maybe one for you. The ortho utilization in the quarter was very impressive. Can you maybe just talk to kind of what's resonating in the market and where you think this could go? It seems like you should still have a lot of traction with some of the recent launches like MA and the marketing initiatives that you guys talked about. I was just curious to get your thoughts on where you think this could ultimately end up.
好的。這樣就合理了。接著 Joe,可能問你一題。本季的矯正科(ortho)使用率(utilization)非常亮眼。你能否談談市場上到底是哪些因素引起共鳴,以及你認為這可能會走到什麼程度?看起來你們在一些近期上市的產品(像 MA)以及你們提到的行銷推動上,應該仍然會有很大的動能。我想聽聽你對最終可能達到的水準有何看法。
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Nathan, overall, when you look at what's going on, I'd say there's 2 prime drivers in that ortho segment. One is what you mentioned is you our MAF product now that was qualified in November of last year. You have our Invisalign Teen product, which we're doing a lot of cases, 7-year-old patients, 8-year-old patients that we really never touched before. So that's obviously a big driver from an increased utilization standpoint. Secondly, I think, is just increasing awareness of the preference of consumers for clear aligners. And I think orthodontists know that and we see more and more orthodontists really adopting that. Thirdly, when you think about the segment overall is, from a long-term standpoint, like we talked about that's our second strategic imperative, is we see a lot of runway in teens. That's why we're having our teen summit coming up this year. We'll have a lot of focus in our top 300 in London this year also on teens, and we see more and more uptake on that as we work with orthos on the teens and we go directly to consumers and parents about it.
Nathan,整體來看,我會說矯正科這個區隔有兩個主要驅動因素。第一個是你提到的:我們的 MAF 產品在去年 11 月已取得資格認定(qualified)。另外還有我們的 Invisalign Teen 產品,我們正在做很多病例——7 歲、8 歲的病患——這些年齡層我們以前幾乎沒有觸及。所以從使用率提升的角度來看,這顯然是一個很大的驅動因素。第二,我認為是消費者對透明牙套(clear aligners)的偏好認知正在提升。我想矯正醫師也知道這點,我們看到越來越多矯正醫師真正開始採用。第三,從長期角度看整個區隔——就像我們談過的,這是我們第二個策略要務——我們在青少年市場仍有很長的成長跑道。這也是為什麼我們今年會舉辦青少年高峰會(teen summit)。今年我們在倫敦的前 300(top 300)活動也會把很多焦點放在青少年上;而且當我們與矯正醫師合作推動青少年病例,並直接向消費者與家長溝通時,我們看到採用度(uptake)越來越高。
Operator
Operator
Our next question is from Glen Santangelo with Guggenheim Securities.
我們的下一個問題來自 Guggenheim Securities 的 Glen Santangelo。
Glen Joseph Santangelo - Analyst
Glen Joseph Santangelo - Analyst
Joe, I just wanted to follow up on the previous sort of ASP question because I almost look at it a little bit differently, right? I mean you clearly had a decent uptick on an international basis and your worldwide ASP was up slightly. Does that kind of imply that North America might have been flat or even maybe down? And I know there's a lot of moving parts and I think, John, you talk about some of those like mix and promotional discounts and FX. Could you just peel back the onion a little bit on North American ASPs and give us a sense because I think it's important given the market's focus on the competitive landscape. So just give us a sense on what's going on there.
Joe,我只是想就前面那個有關 ASP 的問題再追問一下,因為我看待它的角度可能有點不一樣,對吧?我的意思是,你們在國際市場顯然有不錯的上升,而你們的全球 ASP 也小幅上升。這是否某種程度上意味著北美可能持平,甚至可能下滑?我知道這裡面有很多變動因素,我想 John 也提到其中一些,例如產品組合、促銷折扣以及匯率。你能不能把北美 ASP 的情況再多拆解一點,給我們一些感覺?因為考量到市場對競爭態勢的關注,我認為這很重要。所以請你們談談那邊到底發生了什麼。
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
Yes, Glen. When we look at the ASPs, it sounds like you said, up about $10 on a worldwide basis. In North America, slightly down from Q4 but from the standpoint of really coming from a mix standpoint, it's just a matter of how and what type of cases the doctors are taking on, whether it's more comprehensive or some of the low stage. And remember, from a low stage standpoint, those are some of our highest margin rate products. So when we look at that in total, we'll go to where the volume is and what makes sense for our business.
是的,Glen。我們看 ASP 的話,如你所說,全球大約上升了 10 美元。北美方面,相較於第四季略有下降,但主要是來自產品組合的因素——也就是醫師接的病例類型與方式,是較多綜合性病例,還是一些較低階段的病例。而且請記得,從低階段的角度來看,那些其實是我們毛利率最高的一些產品。因此整體來看,我們會把重點放在有量的地方,以及對我們業務最合理的地方。
Glen Joseph Santangelo - Analyst
Glen Joseph Santangelo - Analyst
Maybe I just ask one follow-up question on your utilization within North American orthodontist. You saw a healthy sequential uptick in the number of cases. Maybe -- any idea what drove that? And maybe you could give us a better sense for where maybe market penetration stands now for clear tray aligner and maybe what your market share numbers might look like to give us a sense for how much runway there may be to go?
我再追問一個關於北美矯正科醫師端使用率(utilization) 的問題。你們看到病例數有健康的季對季上升。也許——你們是否知道是什麼驅動了這個變化?另外,也許你們可以更清楚地說明一下,目前透明牙套矯正器(clear tray aligner)的市場滲透率大概到哪裡了,以及你們的市占率數字可能長什麼樣子,讓我們了解未來還有多少成長跑道?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Glen, it's Joe. On the utilization for orthos, think about 2 big vectors there just our new product line in teens, MAF and our Invisalign First product line. It really brings us into about 25% to 30% of the teen market that we couldn't access before we had those products. Overall, I just think we have good momentum in that sense so we're going to continue to see continued increase in utilization as more and more doctors gain confidence in these products.
Glen,我是 Joe。關於矯正科(orthos)的使用率,主要可以從兩個大向量來看:我們在青少年(teens)的新產品線——MAF,以及我們的 Invisalign First 產品線。這些產品讓我們能夠切入約 25% 到 30% 的青少年市場,而在推出這些產品之前,我們是無法觸及那一塊的。整體而言,我認為我們在這方面動能不錯,因此隨著越來越多醫師對這些產品建立信心,我們會持續看到使用率的提升。
Operator
Operator
Our next question is from Ravi Misra with Berenberg Capital Markets.
我們的下一個問題來自 Berenberg Capital Markets 的 Ravi Misra。
Ravi Misra - Analyst
Ravi Misra - Analyst
So I guess just following up on that, Joe. Can we just talk a little bit about how the Invisalign First and mandibular advancement are contributing to that growth rate, in that kind of strong teen growth number that you put there? And a little bit related, can you maybe touch upon what you're seeing out there with the competition and how your strategy is evolving now that the store closure has become underway.
那我想就此再追問一下,Joe。我們能否談談 Invisalign First 與下顎前移(mandibular advancement)在你們所提到的那個強勁青少年成長數字中,對成長率的貢獻是如何?另外也相關地,你能否談談你們在市場上看到的競爭情況,以及在門市關閉開始進行之後,你們的策略現在如何演進?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
First of all, Ravi, I'd just say again the utilization rates that you reference in all and for teens again, it's new product. We still have an underutilization in teens. I mean, we're still in the United States, 9%, 10% from a teens standpoint. I'd say from a clinical standpoint, we can handle 80%, 90% of those cases depending on how you want to rate them. Many of our Invisalign docs say they can do anything in teen that they can in Invisalign. So you have a long way to go from a growth standpoint. From a competitive standpoint, we really don't have competitors in those kinds of products, okay? Those are highly proprietary products that it just takes a lot of history and knowledge to be able to make them and have them functioning well in the marketplace. As far as how we're competing out there with Invisalign stores or wherever. Invisalign stores are what they always have been with how do you drive more demand for our product line. It was in a way, instead of -- we've been advertising to consumers for years. This was a way of just taking those advertisement kind of capabilities and bring them into store and exciting patients moving those patients to doctors. There was nothing different in our business model. I mean it's a shame in the sense of what the arbitrator ruled. But look, we'll respect that decision and we'll move on in the sense of continuing to generate demand the way we know how to generate demand. From a competitive standpoint, SDC is a different kind of competitor. Obviously, they have high growth rates. We have high growth rates, too. We show we can mutually coexist in the marketplace and we continue to both grow.
首先,Ravi,我再說一次,你提到的整體與青少年使用率,主要還是來自新產品。我們在青少年市場仍然存在使用不足的情況。我的意思是,在美國,青少年端大概只有 9%、10% 的滲透。我會說從臨床角度來看,我們可以處理其中 80%、90% 的病例,取決於你怎麼評估。很多我們的 Invisalign 醫師都說,他們在青少年病例上能做的事情,跟在 Invisalign 上能做的事情一樣多。所以從成長角度來看,還有很長的路要走。從競爭角度來看,在這類產品上我們其實沒有競爭對手,好嗎?這些是高度專有(proprietary)的產品,需要很長的歷史與知識累積,才能做得出來並且在市場上運作良好。至於我們如何在市場上與 Invisalign 門市或其他通路競爭。Invisalign 門市一直以來的定位都是:如何為我們的產品線帶來更多需求。某種程度上,這是一種方式——我們多年來一直對消費者投放廣告。而門市只是把那些廣告能力帶進店內,讓患者更有感,並把患者導流到醫師那裡。我們的商業模式沒有任何不同。就仲裁結果而言,確實令人遺憾。但我們會尊重該決定,並繼續以我們熟悉的方式來創造需求。從競爭角度來看,SDC 是一種不同類型的競爭者。顯然他們有很高的成長率。我們也有很高的成長率。我們證明了彼此可以在市場上共同存在,而且我們也會繼續一起成長。
Operator
Operator
Our next question is from John Kreger with William Blair.
我們的下一個問題來自 William Blair 的 John Kreger。
John Charles Kreger - Partner & Healthcare Services Analyst
John Charles Kreger - Partner & Healthcare Services Analyst
So I'd like to go back to China. Can you just talk about the next steps there? What you have to do to continue growing as quickly as you have? We notice that the number of doctors trained in APAC and China declined a little bit compared to where it was at the end of '18. Is that in any way related to the slowing economic outlook in your opinion or is that seasonality? And can you just talk about how you expect the competitive dynamics in China to change now that Straumann is making an entrance via a partnership there?
我想回到中國的話題。你能談談接下來的步驟嗎?你們需要做些什麼,才能繼續維持目前這麼快的成長?我們注意到,APAC 與中國受訓醫師的人數,相較於 2018 年底略有下降。你認為這是否與經濟前景放緩有關,還是只是季節性因素?另外,你能談談隨著 Straumann 透過當地合作夥伴進入市場後,你預期中國的競爭動態會如何改變嗎?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Look, it's -- back to Joe here. China is a great growth market for us. We're manufacturing in China now. We put treatment planning in Chengdu. We handle all of our Chinese doctors right now out of China itself. We have 2 wonderful training centers, one in Shanghai, one in Chengdu. We feel very capable in China. We lead in China. Straumann's move with third- or fourth-tier player from a clear aligner standpoint, I don't see that as dramatic effect on this market now or in the immediate future at all.
我來回答——我是 Joe。中國對我們來說是一個很棒的成長市場。我們現在已經在中國製造。我們在成都設置了治療計畫(treatment planning)。我們目前所有中國醫師的服務都由中國本地來承接。我們有兩個很棒的培訓中心,一個在上海,一個在成都。我們對在中國的能力很有信心。我們在中國處於領先地位。Straumann 與第三或第四梯隊的透明矯正器業者合作的動作,我不認為現在或短期內會對這個市場造成任何顯著影響。
John Charles Kreger - Partner & Healthcare Services Analyst
John Charles Kreger - Partner & Healthcare Services Analyst
Okay. Great. And then just one quick clarifying question on operating margin. So if you strip out the onetime gains and losses that you discussed, does your full year outlook that you discussed a quarter ago for operating margin that's below the long-term outlook? Does that still hold?
好的。很好。然後再一個關於營業利益率(operating margin)的快速釐清問題。如果把你們提到的一次性收益與損失剔除,你們在一季前所談到的、全年營業利益率展望(低於長期展望)是否仍然成立?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Yes.
是的。
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
Yes, it does.
是的,仍然成立。
Operator
Operator
Our next question is from Brandon Couillard with Jefferies.
我們的下一個問題來自 Jefferies 的 Brandon Couillard。
Brandon Couillard - Equity Analyst
Brandon Couillard - Equity Analyst
Joe, a 2-part question on the scanner business. First, we'd like to get your perspective on how you sort of see the competitive landscape developing, a number of new launches out at IDS. Do you anticipate any stepped-up level and just noise or evaluations as customers kind of digest these new intros?
Joe,關於掃描器(scanner)業務有兩個問題。第一,我們想聽聽你對競爭態勢如何發展的看法,因為在 IDS 上有不少新產品發表。你是否預期,當客戶消化這些新推出的產品時,市場上的聲量或評估活動會有所升溫?
And then secondly, could you give us a sense of the relative growth rates in the scanner business between all OUS in North America?
其次,您能否讓我們了解一下,在北美地區,掃描器業務在所有美國以外(OUS)市場之間的相對成長率?
And then, I guess, thirdly, any help you could give us in terms of the expected timing of the U.S. approval for the new iTero 5D?
再來,我想第三點,您能否就新款 iTero 5D 在美國獲批的預期時間點提供一些協助?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Let me start with your broader question on the scanner business is, look, we really feel good about our scanner. I mean 5D leads, I mean, obviously you see the 3Shape product came out but you got 2 separate scans that kind of use a near infrared. And we were so focused on workflow with GPs. We've just known over the years that, goodness, GPs time is such an important commodity in that sense and you want to do things as fast as you possibly can. So combining the near-infrared together for caries detection and tooth cracking, together with just a normal digital scan is a big breakthrough for us in the industry. And we've gotten great feedback. Obviously, they're starting off well. From a standpoint of U.S. approval, it's the FDA. I don't want to talk too much about it. But there are some issues in a sense of how the FDA wants this one to be designed from a disease-control standpoint. Look, we have a good vector on what needs to be done. It's going to take a little bit longer just like our MAF product did. But we're confident in I would say late fourth quarter, early first quarter of next year we'll be able to get approval.
我先回答您關於掃描器業務較宏觀的問題:我們對自家的掃描器確實感到很有信心。我的意思是,5D 領先;當然你也看到 3Shape 的產品推出了,但它是兩次分開掃描,某種程度上使用近紅外。而我們一直非常專注於全科醫師(GP)的工作流程。多年來我們一直知道,天啊,GP 的時間在這方面是非常重要的資源,你希望能盡可能快地把事情做完。因此,把用於齲齒偵測與牙齒裂紋檢測的近紅外,與一般的數位掃描結合在一起,對我們而言是產業上的一大突破。而我們也收到了非常好的回饋。顯然,一開始的表現就很好。至於美國核准方面,是 FDA 的事。我不想談太多。但在某種程度上,FDA 從疾病控制的角度,對這一款的設計方式有一些要求。我們對需要做什麼有很清楚的方向。它會花更久一點,就像我們的 MAF 產品一樣。但我們有信心,我會說在第四季末、或明年第一季初就能取得核准。
Brandon Couillard - Equity Analyst
Brandon Couillard - Equity Analyst
And a couple for John, housekeeping items. First, could you quantify the impact of the China facility on gross margins in the first quarter? Secondly, were there any legal or corporate expense or corporate reorg expenses absorbed in the first quarter? And then lastly, the $0.10 SDC equity gain in 2Q. Just confirm, is that below the line?
另外有幾個給 John 的問題,屬於例行事項。第一,您能否量化第一季中國廠對毛利率的影響?第二,第一季是否吸收了任何法律費用、公司費用或公司重組費用?最後,第二季 SDC 股權收益每股 0.10 美元。請確認,那是列在業外(below the line)嗎?
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
Well, I can answer that one first. Yes, that's below the line. That's the equity gain that we will have. And then the corporate restructuring cost, very small amount in Q1. It really starts in Q2 and handles the rest of the year. And then in terms of the China gross margin or the impact on costs. We saw higher utilization in those plants, drives efficiencies and we see that come through to our bottom line. So as we described earlier, it starts in Q1 and it progresses through the year.
我可以先回答最後那個。是的,那是列在業外。那就是我們將會認列的股權收益。至於公司重整成本,第一季金額非常小。主要是從第二季開始,並涵蓋今年剩餘時間。再來談中國的毛利率或對成本的影響。我們看到那些工廠的產能利用率提高,帶動效率提升,並反映到我們的最終獲利。所以如同我們先前所說,從第一季開始,並在全年逐步改善。
Operator
Operator
Our next question is from Elizabeth Anderson with Evercore.
下一個問題來自 Evercore 的 Elizabeth Anderson。
Elizabeth Hammell Anderson - Associate
Elizabeth Hammell Anderson - Associate
Could you talk a little bit about the feedback that you guys have received on the doctor-owned experience centers now that they're sort of switching more and more to that strategy?
你們能否談談,隨著你們越來越轉向這項策略,對於由醫師持有的體驗中心所收到的一些回饋?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Elizabeth, it's Joe. We have about 2 of those out there right now. Feedback is good. I mean, we've had Invisalign stores out there for years basically. And these are ones they're just dedicated Invisalign stores with brand and all and feedback has been terrific. Uptake has been good. So overall, it's a good place for us to invest.
Elizabeth,我是 Joe。我們目前大概有 2 個這樣的據點。回饋不錯。我的意思是,我們多年來基本上一直都有 Invisalign 門市。而這些就是專門的 Invisalign 門市,有品牌形象等等,回饋非常好。採用情況也不錯。所以整體而言,這是我們值得投資的地方。
Elizabeth Hammell Anderson - Associate
Elizabeth Hammell Anderson - Associate
Okay. And the new plan for a sort of that growth going forward, you don't anticipate sort of any major changes versus what you've sort of been seeing recently with those?
好的。那關於未來這類成長的新計畫,你不預期相較於你們最近看到的情況會有任何重大變化,對嗎?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
No. I think we'll just -- we'll continue with the pace that we've been going and there's a lot of interest out there. We're just working through it right now. But overall, the interest from an orthodontic standpoint has been extremely good and also from the GP practices.
不會。我想我們會——我們會維持目前的推進速度,而且市場上有很大的興趣。我們現在只是正在逐步推進。但整體而言,從齒顎矯正的角度來看興趣非常高,GP 診所端也是如此。
Operator
Operator
Our next question is from Steven Valiquette with Barclays.
下一個問題來自 Barclays 的 Steven Valiquette。
Steven James Valiquette - Research Analyst
Steven James Valiquette - Research Analyst
So I just have a question here around the Straumann settlement. The $35 million initial payment. I mean that seems pretty straightforward. But for the extra nonbinding part of the agreement, it seems like the potential for Straumann to sell 5,000 extra iTero scanners would be much more positive for Align versus just receiving an extra $16 million from them. So I guess the questions are, first, do you agree or disagree with that? And also secondarily, just from a Straumann perspective, what would be the incentives for them to sell iTero and sort of just paying you the $16 million? So just curious to get more color around this.
我這裡有個關於 Straumann 和解的問題。3,500 萬美元的初始付款看起來很直接。但就協議中額外的非約束性部分而言,看起來 Straumann 若能多賣 5,000 台 iTero 掃描器,對 Align 的正面效益會遠大於僅僅再收到他們額外的 1,600 萬美元。
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Steve, it's Joe. First of all, when you look at Straumann, they don't -- they have their own internal scanner but it really doesn't fit the broad application base that you need for both clear aligners and also for the restorative aspect of GP. So they primarily use 3Shape of those kinds of scans today. So your comment about which is better, the $16 million or this. It's a good question. I mean you have to assume that the 5,000 that they would sell, would be 5,000 we can't sell. I mean that's not necessarily a true or discrete variable in this whole equation. So look, ideally, I think, having the scanners sold by Straumann and having a good restorative workflow together would be helpful. But I would -- it's not a live-or-die proposition. I feel we have a good distribution in the marketplace, we have good coverage in 3 different regions and we'll be able to function well in either scenario.
Steve,我是 Joe。首先,談到 Straumann,他們有自家的內部掃描器,但它並不符合你在透明矯正器以及 GP 修復治療面向所需要的廣泛應用基礎。所以他們目前主要使用 3Shape 這類掃描器。至於你提到哪個比較好:1,600 萬美元還是這個方案。這是個好問題。我的意思是,你必須假設他們會賣出的那 5,000 台,會是我們賣不出去的 5,000 台。但在整個方程式裡,這不一定是個真實或可明確切割的變數。所以理想狀況下,我認為由 Straumann 來銷售掃描器,並共同建立良好的修復工作流程,會是有幫助的。但我會說——這不是非成敗不可的命題。我覺得我們在市場上有良好的通路,在三個不同區域也有良好的覆蓋,我們在任何一種情境下都能運作得很好。
Operator
Operator
Our next question is from Matt O'Brien with Piper Jaffray.
下一個問題來自 Piper Jaffray 的 Matt O'Brien。
Kevin Michael Farshchi - Research Analyst
Kevin Michael Farshchi - Research Analyst
This is Kevin on for Matt today. First one, just quickly on iTero. Assume the seasonality in Q1, likely the low the watermark there and assume the outlook for the sequential increase in Q2 that you provided. But can you put any numbers or a trend around the iTero growth for the second half of the year. The comps there are obviously difficult. But I assume you have a bigger specialized sales force just on that and then your lapping some DSO partnerships.
今天由 Kevin 代替 Matt 提問。第一個,快速問一下 iTero。考量第一季的季節性,可能是全年低點,並且考量你們對第二季提出的環比成長展望。但你能否就下半年 iTero 的成長提供一些數字或趨勢?那段期間的比較基期顯然很具挑戰。但我想你們在這方面有更大的專業銷售團隊,而且你們也會跨過一些 DSO 合作的比較基期。
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
Yes, Kevin. This is John. We saw good growth in Q1. What we expect is to be able to continue to globally be able to have more and more iTeros sold. We think it's a great scanner. New 5D and so on really contributes to that growth. But we've seen good growth so far. Really no change in how we think about it for the total year. We're just going to continue to expand and work through as many doctors as possible.
是的,Kevin。我是 John。我們在第一季看到不錯的成長。我們預期能夠在全球持續賣出越來越多的 iTero。我們認為這是一款很棒的掃描器。新的 5D 等等確實有助於帶動成長。但到目前為止我們已經看到良好的成長。我們對全年整體的看法沒有改變。我們會持續擴張,並盡可能觸及更多醫師。
Kevin Michael Farshchi - Research Analyst
Kevin Michael Farshchi - Research Analyst
Okay. It sounds great. If I could squeeze one more in for Joe. It seems like the initiatives in Brazil are continuing to ramp up with those 3,000 docs trained. And you've obviously been highly underindexed there historically as a percentage of Americas despite it being a big market. Can you frame up that opportunity a little bit and talk about the type of revenue contribution you can get this year and in the coming years from that region? Is it upside to the plan? How do you think about that region?
好的。聽起來很棒。如果我可以再替 Joe 多問一題。看起來巴西的各項計畫在培訓了那 3,000 位醫師之後仍在持續加速推進。而且很明顯地,儘管美洲市場很大,但你們過去在那裡的占比一直相對偏低。你能否更具體地說明一下那個機會,並談談今年以及未來幾年該地區可能帶來的營收貢獻類型?這會是高於計畫的上行空間嗎?你們如何看待那個地區?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Well, I mean, I think it's in our plan for 2019, is already baked in there from Brazil and Latin America standpoint. I can tell by your question, you do recognize the opportunity that we have in Latin America and also Brazil, given the focus on orthodontics in both of those regions. Look, and your comment also, we were late to the game there and that's why you see us making significant investments now in the sense of training doctors, putting people in place and building infrastructure there. So we haven't broken out those numbers yet. When they become material to the business, we'll do that. But right now, we're not making any projections or specifics about it. But rest assured, as you know, this is a big opportunity for us. It's a good product at the right time. And we feel we have good leadership there and good momentum.
嗯,我的意思是,我認為從巴西與拉丁美洲的角度來看,這已經納入我們 2019 年的計畫之中,也就是已經反映在裡面了。從你的問題我看得出來,你確實認知到我們在拉丁美洲以及巴西的機會,考量到這兩個地區對齒顎矯正的重點投入。你也提到一點:我們在那裡起步較晚,所以你現在看到我們正在進行顯著投資,包括培訓醫師、配置人員以及建立當地基礎設施。因此我們目前還沒有把那些數字單獨拆出來。等到它們對業務變得具實質性時,我們會這麼做。但就目前而言,我們不會對此做任何預測或提供具體細節。不過請放心,如你所知,這對我們而言是一個很大的機會。這是一個在對的時間推出的好產品。而且我們覺得當地有良好的領導團隊與不錯的動能。
Operator
Operator
Our next question is from Michael Ryskin with Bank of America.
我們的下一個問題來自美國銀行(Bank of America)的 Michael Ryskin。
Michael Leonidovich Ryskin - Associate
Michael Leonidovich Ryskin - Associate
Just 2 real quick ones. One on the mandibular advancement. It's been a few months now since it's been out in the States. And you mentioned that you saw a positive adoption response in 1Q. Could you go a little bit deeper? Did it show up materially in the numbers? Do you think it contributed? And sort of how does it feel going into the ramp for the rest of the year?
我有兩個很快的問題。第一個是關於下顎前移(mandibular advancement)。它在美國上市已經幾個月了。你提到在第一季看到正面的採用反應。你能否再深入一點?它是否在數字上有實質反映?你認為它有貢獻嗎?以及在今年剩餘時間的放量爬坡上,你們的感受如何?
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
Mike, this is John. It certainly helps. It's a slow adoption. I mean these are doctors that -- they just started trying some of these cases. They want to see and experience it for themselves to be able to see that it works in a way they want. So it's a slow rollout and adoption but it gets at some of the key parts of our business that we want to grow, which is teen.
Mike,我是 John。它確實有幫助。採用速度是慢的。我的意思是,這些醫師——他們才剛開始嘗試其中一些病例。他們想親自看到並體驗,確認它能以他們想要的方式發揮效果。所以推廣與採用是逐步進行、較慢的,但它切中我們希望成長的業務關鍵之一,也就是青少年(teen)市場。
Michael Leonidovich Ryskin - Associate
Michael Leonidovich Ryskin - Associate
Got it. I was just trying to -- if that contributed to the North American ortho boost in the quarter. And then a quick follow-on. The China fabrication facility you mentioned still being underutilized, continues to ramp. Any thoughts for when you think you could hit full ramp or close to it? Is it later this year, is it early 2020? Just to give us a sense for how that moves through.
了解。我只是想確認——它是否對本季北美齒顎矯正的成長提升有所貢獻。然後再追問一個。你提到中國的製造工廠仍然未充分利用、並持續爬坡。你們對何時能達到滿載或接近滿載有什麼想法嗎?會是在今年稍晚,還是 2020 年初?只是想讓我們對進展節奏有個概念。
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
Yes, Mike. This is John again. So we'll see a progression and we saw a good improvement in Q1. And it will continue to improve as you utilize that facility more and more. But that'll take the rest of this year.
是的,Mike。我又是 John。所以我們會看到逐步的進展,而且我們在第一季看到不錯的改善。隨著你越來越多地利用那座工廠,情況會持續改善。但這會需要今年剩下的時間。
Operator
Operator
Our next question is from Richard Newitter with SVB Leerink.
我們的下一個問題來自 SVB Leerink 的 Richard Newitter。
Jaime Lynn Morgan - Associate
Jaime Lynn Morgan - Associate
This is Jaime on for Rich. I just wanted to circle back on competition. I know some of your competitors have recently launched more price-favorable lines geared towards the GP channel. So I was wondering if you're seeing or running into competition a little bit more in that channel and then also just kind of a sense of the ortho channel as well as you're now several quarters into seeing some competition.
我是 Jaime,代 Rich 提問。我想回到競爭的話題。我知道你們的一些競爭對手最近推出了更具價格優勢、面向 GP 通路的產品線。所以我想請問,你們是否在該通路看到或遇到更多競爭?另外,隨著你們已經連續好幾季面對一些競爭,也想請你談談齒顎矯正(ortho)通路的情況。
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Jaime, it's Joe. Just a quick question for you. Would you tell me who that competitor is with the price-favorable lines in GP?
Jaime,我是 Joe。我先快速問你一個問題。你能告訴我是哪一家競爭對手在 GP 通路推出了更具價格優勢的產品線嗎?
Jaime Lynn Morgan - Associate
Jaime Lynn Morgan - Associate
I believe Henry Schein had been -- they had launched a new product geared...
我相信是 Henry Schein——他們推出了一個面向……的新產品……
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Yes. We haven't really seen Schein or felt Schein in the marketplace at all. And we don't even know what their pricing is, frankly. And so we really haven't had to respond to that piece. I think if you look at the marketplace, you'd say that ClearCorrect traditionally has been in that GP segment. They're obviously owned by Straumann now. Straumann has been taking them throughout that channel. But we really haven't felt a higher degree of competitive pressure since [that piece] either. So I just found your question interesting. I know there's a lot of speculation out there right now, but we don't necessarily feel that. And remember, ClearCorrect always had a price-favorable line from a GP standpoint. And we've basically been able to fight that with technology and coverage in the marketplace.
是的。我們其實完全沒有在市場上看到 Schein,或感受到 Schein 的存在。坦白說,我們甚至不知道他們的定價是多少。因此我們也沒有必要針對那一塊做出回應。我想如果你看整個市場,你會說 ClearCorrect 傳統上一直在 GP 這個區隔。他們現在顯然已被 Straumann 收購。Straumann 一直在透過那個通路推動他們。但自從[那件事]以來,我們也沒有感受到更高程度的競爭壓力。所以我覺得你的問題很有意思。我知道現在外界有很多揣測,但我們不一定有那樣的感受。而且請記得,從 GP 的角度來看,ClearCorrect 一直都有較具價格優勢的產品線。而我們基本上能以技術與市場覆蓋來與之競爭。
Operator
Operator
Our last question is from Kevin Caliendo with UBS Investment Bank.
我們最後一個問題來自瑞銀投資銀行(UBS Investment Bank)的 Kevin Caliendo。
Kevin Caliendo - Equity Research Analyst of Healthcare IT and Distribution
Kevin Caliendo - Equity Research Analyst of Healthcare IT and Distribution
Just any color around the doctors trained in the quarter? I noticed sequential decline. There's always some seasonality to this but just the number of docs trained was pretty meaningfully lower, both OUS and in the Americas. Just any color around that?
想請問本季受訓醫師人數方面有沒有什麼補充說明?我注意到環比下滑。我知道這裡面有一些季節性,但受訓醫師數量確實明顯較低,不論是美國以外(OUS)或美洲地區都是。對此有沒有什麼補充?
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
Kevin, this is John. From a doctor standpoint, Q1 is typically lower from a training standpoint. So things build as you go through the year. And we saw that from Q4 to Q1. But nothing more. We want to work with doctors that want to come with cases and really get into being able to use more and more Invisalign. So some of it is just the timing of making that all happen but nothing more than that.
Kevin,我是 John。從醫師培訓的角度來看,第一季通常是較低的。所以隨著年度推進,情況會逐步回升。我們也看到從第四季到第一季的這種變化。除此之外沒有更多特別之處。我們希望與那些願意帶著病例來、並真正投入、能夠使用越來越多 Invisalign 的醫師合作。所以其中一部分只是讓這些事情發生的時間點安排,但沒有其他額外因素。
Shirley Stacy - VP of Corporate Communications & IR
Shirley Stacy - VP of Corporate Communications & IR
Well, thank you, everyone. This wraps up our first quarter conference call. If you have any follow-up questions, please follow up with Investor Relations. We hope you have a great day. We'll look forward to seeing you at future meetings.
好的,謝謝各位。這就結束我們第一季的電話法說會。如果你有任何後續問題,請與投資人關係部門聯繫。祝各位有美好的一天。期待在未來的會議上與各位再見。
Operator
Operator
Thank you. This concludes today's conference. You may disconnect your lines at this time, and thank you for your participation.
謝謝。今天的會議到此結束。您現在可以掛斷電話線,感謝您的參與。